Skip to main content
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 2014 Apr 1;92(7):499–511AD. doi: 10.2471/BLT.13.127639

Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries

Est-il possible de faire des économies et d'obtenir des gains en termes d'efficacité dans les services anti-VIH? Un examen systématique des éléments de preuve dans les pays à revenu faible et intermédiaire

¿Hay margen para el ahorro de costes y el aumento de la eficacia en los servicios de VIH? Un examen sistemático de la evidencia de países con ingresos bajos y medios

هل يوجد نطاق لتحقيق وفورات التكاليف ومكاسب الكفاءة في خدمات فيروس العوز المناعي البشري؟ استعراض منهجي للبيّنات المستمدة من البلدان المنخفضة الدخل والبلدان المتوسطة الدخل

艾滋病毒服务中是否有实现节本增效的余地?中低收入国家的系统评价

Существуют ли возможности для экономии средств и повышения эффективности в сфере ВИЧ-услуг? Систематический обзор данных из стран с низким и средним уровнями доходов

Mariana Siapka a, Michelle Remme a, Carol Dayo Obure a, Claudia B Maier b, Karl L Dehne b, Anna Vassall a,
PMCID: PMC4121865  PMID: 25110375

Abstract

Objective

To synthesize the data available – on costs, efficiency and economies of scale and scope – for the six basic programmes of the UNAIDS Strategic Investment Framework, to inform those planning the scale-up of human immunodeficiency virus (HIV) services in low- and middle-income countries.

Methods

The relevant peer-reviewed and “grey” literature from low- and middle-income countries was systematically reviewed. Search and analysis followed Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.

Findings

Of the 82 empirical costing and efficiency studies identified, nine provided data on economies of scale. Scale explained much of the variation in the costs of several HIV services, particularly those of targeted HIV prevention for key populations and HIV testing and treatment. There is some evidence of economies of scope from integrating HIV counselling and testing services with several other services. Cost efficiency may also be improved by reducing input prices, task shifting and improving client adherence.

Conclusion

HIV programmes need to optimize the scale of service provision to achieve efficiency. Interventions that may enhance the potential for economies of scale include intensifying demand-creation activities, reducing the costs for service users, expanding existing programmes rather than creating new structures, and reducing attrition of existing service users. Models for integrated service delivery – which is, potentially, more efficient than the implementation of stand-alone services – should be investigated further. Further experimental evidence is required to understand how to best achieve efficiency gains in HIV programmes and assess the cost–effectiveness of each service-delivery model.

Introduction

To reach the Millennium Development Goals for human immunodeficiency virus (HIV) infection1 and the targets of the Political Declaration on HIV and Acquired Immunodeficiency Syndrome (AIDS),2 many low- and middle-income countries still need to scale up essential HIV services. Given the scarce financial resources available and competing donor priorities, methods to improve efficiency in the delivery of HIV services are gaining increased global attention.36

In general, an “efficient” HIV service cannot be improved without the further use of existing resources and cannot be maintained at its current level with fewer resources. The word “efficiency” has several dimensions when applied to HIV services. For example, economic theory distinguishes between efficiency from improving social welfare – the “allocative” efficiency that is often assessed in the health sector in terms of cost–effectiveness – and a more contained definition of efficiency that examines how best to use resources to provide individual services – the “technical” efficiency that is commonly assessed in terms of the unit costs of a service. Two potential areas for improving technical efficiency are service scale and service scope. “Economies of scale” are the reductions in the unit cost of a service that might be achieved when the volume of that service’s provision is increased, whereas “economies of scope” are the reductions in the unit cost of a service that might be observed when that service is provided jointly with other services.3,4,712

There have been several recent reviews of the data available on the costs and cost–effectiveness of HIV interventions.3,4,713 Most of these reviews were focused on allocative efficiency.3,4,7,9,12 The results of the few previous studies on the technical efficiency of HIV services indicate not only that there is considerable variation – between service providers and between settings – in the unit costs of providing similar HIV services, but also that there is, in general, much scope for improving the technical efficiency of HIV services.7,9,14 However, these reviews are outdated or were only partial in their coverage of possible interventions.

Given the current interest of policy-makers in reducing the costs of HIV services, there is now an urgent need to update and synthesize the data on the technical efficiency of HIV services. We therefore present here a systematic literature review of the costs of the six basic programmatic activities of the Strategic Investment Framework of the Joint United Nations Programme on HIV/AIDS (UNAIDS): antiretroviral therapy (ART) and counselling and testing; “key-population” programmes – that is, programmes that target groups of individuals who are at particularly high risk of HIV infection; condom distribution and social marketing; voluntary medical male circumcision; programmes to eliminate HIV infections among children and to keep their mothers alive; and programmes of behaviour-change communications targeted at young adults and the general population.15

Methods

Search strategy and selection criteria

We conducted a systematic review of the peer-reviewed and “grey” literature on HIV services in low- and middle-income countries by following the search and analysis process recommended in the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.16 The PubMed and Eldis databases and the Cochrane library were searched, using AIDS, HIV, acquired immunodeficiency syndrome, cost, cost analysis, efficiency, economies of scale and economies of scope as the search terms. Searches were limited to English-language articles published between January 1990 and October 2013. Manual searches of the web sites of key organizations were also carried out to identify grey literature and minimize the risk of publication bias (Fig. 1).17 The World Bank’s definitions were used to categorize countries as low- or middle-income.18 Although conference abstracts, editorials, commentaries and “letters to the editor” were used to identify related studies – through a “snowballing” process – any data found only in such publications were excluded from the systematic review. Studies of mathematical models that provided no primary data on costs were also excluded. Bibliographies and previous systematic reviews were examined to identify additional studies of relevance. Authors were contacted directly if the full text of a published paper, unpublished paper or report was not available to us. Two researchers screened the identified citations, reviewed the full texts of potentially eligible articles and selected the final articles for inclusion. Data were extracted by one researcher before being checked by another researcher. Whenever there was uncertainty or disagreement about the inclusion of a study, the authors discussed the study until a consensus was reached.

Fig. 1.

Flowchart for the selection of studies on costs of the six basic programmes of UNAIDS Strategic Investment Framework

MTCT: elimination of mother-to-child transmission; HIV: human immunodeficiency virus.

Note: Some studies included costing data on more than one type of intervention.

Fig. 1

Data on the unit costs of the HIV services of interest were available for seven upper-middle-income countries, 14 lower-middle-income countries and 12 low-income countries. Most of the included studies were categorized as cost analyses but cost data were also extracted from cost–effectiveness and cost–benefit analyses, resource-needs estimations and broad evaluation studies. Authors of only 30 of the included studies undertook sensitivity analyses to assess the levels of uncertainty in their cost estimates.

Data extraction and quality of studies

The quality of studies was assessed using Drummond’s checklist.19 Additional criteria for the assessment of study quality were included whether all relevant costs were included, the source of the cost estimates, whether a sensitivity analysis was conducted and, if so, what type of sensitivity analysis was used, and the scale of the study – in terms of the number of sites for which costings were made. As we wished to evaluate the overall quality of studies, we included all studies with some empirical basis, irrespective of their quality. However, we took study quality into account when reporting the strength of the evidence.

We used the unit costs of service provision – at the health-provider level – as our primary comparative statistic. However, we also noted whether the data from each study included other, “above-service” costs, such as the out-of-pocket expenses of clients using a particular HIV service. We took a narrative approach in our data synthesis, as has been recommended for reviews of health systems and organizational interventions.17

For the purposes of the systematic review, all reported costs were adjusted to United States dollar (US$) values for the year 2011.

Results

Summary of studies

We identified 7108 unique citations of potential relevance and selected 131 of these for full-text review (Fig. 1). Overall, 82 studies met the inclusion criteria: 65 reported in peer-reviewed journals and 17 reported in the grey literature (Table 1). Most (n = 63) of the included studies were classified as fully empirical and 34 included all relevant costs. Costing methods varied between studies but included a “top-down” approach, a “bottom-up” approach and a combination of both of these approaches. Together, the 82 included studies covered 92 unit-cost analyses that related to ART (n = 34), key population programmes (n = 14), HIV counselling and testing (n = 22), programmes to eliminate HIV infections among children and to keep their mothers alive (n = 10), male circumcision (n = 7), condom distribution (n = 4) or behaviour-change communications (n = 1). Many studies were excluded because they did not relate to core HIV or AIDS services, were not conducted in a low- or middle-income country or did not report empirical costs.

Table 1. Quality of studies included in the systematic review.

Quality criterion No. of studies
Antiretroviral therapy Behaviour-change communication Condom promotion and distribution Elimination of MTCT HIV counselling and testing Key populations Voluntary medical male circumcision
Publication type
Peer-reviewed article 28 1 4 8 16 14 1
Grey literature 6 0 0 2 6 0 6
Focus of study
Cost–effectiveness analysis 7 1 2 4 5 5 6
Cost–benefit analysis 1 0 0 0 0 0 0
Cost analysis 20 0 1 5 15 8 0
Cost analysis and resource-needs estimation 5 0 0 0 0 0 0
Programme evaluation 1 0 1 1 0 0 1
Resource-needs estimation 0 0 0 0 2 1 0
Costing scale
National models 0 0 2 1 1 4 0
Single site 15 0 0 0 5 0 0
Small sample (≤ 30 sites) 15 1 2 9 16 9 7
Large sample (> 30 sites) 4 0 0 0 0 0 0
Empirical or modelled costs
Empirical 24 1 4 5 17 10 3
Modelled from empirical study data 10 0 0 5 5 4 4
Costs included
Single cost category (e.g. drugs) 3 0 1 2 3 3 7
Salaries and recurrent costs 13 0 0 2 8 3 0
Salary, non-salary and capital costs 12 1 3 5 8 8 0
Upstream support and systems costs 5 0 0 1 3 0 4
Uncertainty analysis
None 28 0 2 6 15 6 5
Univariate sensitivity analysis 3 0 0 4 4 6 1
Univariate and multivariate sensitivity analyses 3 1 2 0 2 2 0
Results of sensitivity analysis not shown 0 0 0 0 1 0 1

MTCT: mother-to-child transmission; HIV: human immunodeficiency virus.

Table 2, Table 3, Table 4, Table 5, Table 6, Table 7 and Table 8 provide summaries of costs reported in the literature that we reviewed. Further details can be found in Table 9, Table 10, Table 11, Table 12, Table 13, Table 14 and Table 15 (available at: http://www.who.int/bulletin/volumes/92/7/13-127639) and in Appendix A (available at: http://researchonline.lshtm.ac.uk/1620414/). The costs reported in the included studies were generally restricted to the unit costs of one or more HIV services at site level. The reporting of “above-service” costs varied and was always only partial. Most studies included the costs of activities such as training and supervision,36,37 but the costs of several other activities, such as the maintenance of a drugs supply chain, transportation and technical support, were rarely included.

Table 2. Summary of selected mean unit costs of antiretroviral therapy.

Region and referencea Country Cost per patient-year, US$b
Pre-ART ART
Drugs excluded Regimen unclear First-line Second-line
Africa – eastern and southern
Menzies et al. (2011)20 Botswana 200.16 343.87c
Bikilla et al. (2009)21 Ethiopia 137.09 82.70 305.50d
Kombe et al. (2005)22 Ethiopia 268.01 812.15
Marseille et al. (2011)23 Ethiopia 147.81
Menzies et al. (2011)20 Ethiopia 153.97 170.40c 660.03c
Cleary et al. (2007)24 Lesotho 18.00 33.57e or 41.28f 900.50c 1285.90c
Cleary et al. (2006)25 South Africa 566.46 944.51c,g 914.99c 1746.31c
Deghaye et al. (2006)26 South Africa 745.66 1325.81
Harling et al. (2007)27 South Africa 545.60
Harling and Wood (2007)28 South Africa 444.97 1323.59h,i,j 2010.82h,i,j
Rosen et al. (2008)29 South Africa 545.42 1033.98
Vella et al. (2008)30 South Africa 107.34h 207.30h
Kevany et al. (2009)31 South Africa 1815.98d
Martinson et al. (2009)32 South Africa 1206.91 773.26k 1849.45k
Long et al. (2010)33 South Africa 311.50 1087.65
Long et al. (2011)34 South Africa 565.59
Babigumira et al. (2009)35 Uganda 525.37l
Jaffar et al. (2009)36 Uganda 415.80m 855.33m
Menzies et al. (2011)20 Uganda 145.76 186.82 972.08c
Bratt et al. (2011)37 Zambia 359.62n
Africa – western and central
Hounton et al. (2008)38 Benin 398.26 1347.88o
Renaud et al. (2009)39 Burundi 701.78 1017.07j
Kombe et al. (2004)40 Nigeria 443.02 879.00
Partners for Health Reformplus (2004)41 Nigeria 761.13 1881.20
Menzies et al. (2011)20 Nigeria 265.86 347.98c 883.80c
Aliyu et al. (2012)42 Nigeria 210.70p
Asia and Pacific
Gupta et al. (2009)43 India 191.63 380.00
John et al. (2006)44 India 130.87 451.44
Kitajima et al. (2003)45 Thailand 42.99i 407.26d
Menzies et al. (2011)20 Viet Nam 176.56 144.73 948.47c
Caribbean
Koenig et al. (2008)46 Haiti 580.45 1151.46j
Latin America
Marques et al. (2007)47 Brazil 2757.65 5875.46
Aracena-Genao et al. (2008)48 Mexico 8536.18 8065.84 7145.01
Bautista et al. (2003)49 Mexico 835.00 1047.87 4278.00q
Contreras-Hernandez et al. (2010)50 Mexico 2006.58d
Northern Africa and Middle East
Loubiere et al. (2008)51 Morocco 415.72r 1155.85r

ART: antiretroviral therapy; US$: United States dollars.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Adjusted to the dollar values for the year 2011.

c Mean annualized costs for established adult ART patients.

d Mean inpatient and outpatient costs.

e First-line regimen.

f Second-line regimen.

g Mean value excluding costs of first- and second-line drugs and other health services – such as hospitalization.

h Per patient-year of observation.

i Mean annual cost of first 2 years of post-ART care.

j Based on both first- and second-line regimens.

k Excluding first month of initiation.

l Cost of ART was assumed to be the mean cost of first-line drugs, which was estimated – in the values for 2007 – at US$ 237.50 per patient-year.

m Mean costs of home- and facility-based care.

n Mean for first year ART across all drug regimens and facility types.

o Based on a mean number of 1000 people treated per year and annual provision of services to 14 000.

p Based on the assumption that 78% of patients were on the first-line regimen.

q Mean annual cost of first 3 years of post-ART care.

r Mean value across different CD4+ T-lymphocyte count groups.

Table 3. Summary of selected mean unit costs of behaviour-change communications.

Region and referencea Country Cost per person reached, US$b
Billboards Peer education Magazines Radio broadcasts Public outreach events
Africa – western and central
Hsu et al. (2013)52 Benin 25.73 39.98 18.62 4.62 2.35

US$, United States dollars.

a The region shown is one defined by the UNAIDS (Joint United Nations Programme on HIV/AIDS).

b Adjusted to the dollar values for the year 2011. For magazines, radio broadcasts and public outreach events, the corresponding costs per person reporting systematic condom use were US$ 22.83, US$ 25.73 and US$ 31.94, respectively.

Table 4. Summary of selected mean unit costs of condom promotion and distribution.

Region and referencea Country Cost, US$b
Per person reached Per condom sold Per condom distributed
Africa – eastern and southern      
Söderlund et al. (1993)53 Uganda     0.34
Terris-Prestholt et al. (2006)54 Uganda   0.12  
Terris-Prestholt et al. (2006)55 United Republic of Tanzania   1.54  
Söderlund et al. (1993)53 Zimbabwe   0.97 0.16
Africa – western and central      
Söderlund et al. (1993)53 Cameroon     0.54
Söderlund et al. (1993)53 Democratic Republic of the Congo   0.18  
Söderlund et al. (1993)53 Ghana   0.13  
Asia and Pacific      
Dandona et al. (2010)56 India 1.54    
Söderlund et al. (1993)53 Indonesia   0.07  
Caribbean      
Söderlund et al. (1993)53 Dominican Republic   0.21  
Latin America      
Söderlund et al. (1993)53 Bolivia   0.72  
Söderlund et al. (1993)53 Brazil     1.12
Söderlund et al. (1993)53 Côte d’Ivoire   0.24  
Söderlund et al. (1993)53 Ecuador   0.29  
Söderlund et al. (1993)53 Mexico   0.41  
Northern Africa and Middle East      
Söderlund et al. (1993)53 Morocco   0.81  

US$: United States dollars.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Adjusted to the dollar values for the year 2011.

Table 5. Summary of selected mean unit costs of human immunodeficiency virus counselling and testing.

Region and referencea Country Cost, US$b
Per client Per person tested
Africa – eastern and southern    
Kombe et al. (2005)22 Ethiopia 4.97  
Twahir et al. (1996)57 Kenya 15.02  
Sweat et al. (2000)58 Kenya 35.20  
Forsythe et al. (2002)59 Kenya 61.72  
John et al. (2008)60 Kenya 7.25c  
Liambila et al. (2008)61 Kenya 21.60  
Negin et al. (2009)62 Kenya 6.77  
Grabbe et al. (2010)63 Kenya 22.10  
Obure et al. (2012)64 Kenya 7.96  
McConnel et al. (2005)65 South Africa 72.35  
Hausler et al. (2006)66 South Africa 2.64d 3.42
Obure et al. (2012)64 Swaziland 11.52  
Terris-Prestholt et al. (2006)54 Uganda 32.62e  
Menzies et al. (2009)67 Uganda 14.33  
Tumwesigye et al. (2010)68 Uganda 7.52  
Sweat et al. (2000)58 United Republic of Tanzania 38.21  
Bratt et al. (2011)37 Zambia 18.82  
Africa – western and central    
Kombe et al. (2004)40 Nigeria   8.89
Aliyu et al. (2012)42 Nigeria 7.52  
Asia and Pacific    
Dandona et al. (2005)69 India 9.76e  
Das et al. (2007)70 India 2.61  

US$: United States dollars.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Adjusted to the dollar values for the year 2011.

c Mean cost of individual and “couple” counselling of all women.

d Per client pre- and post-test counselled.

e Per client post-test counselled.

Table 6. Summary of selected mean unit costs of key-population programmes.

Region and referencea Country Cost per person reached, US$b
Commercial sex workers Men who have sex with men Truck drivers Injecting drug users Peer health workers Prisoners
Africa – eastern and southern
Moses et al. (1991)71 Kenya 123.36
Chang et al. (2013)72 Uganda 16.21c
Asia and Pacific
Guinness et al. (2010)73 Bangladesh 9.93
Dandona et al. (2005)74 India 16.52
Guinness et al. (2005)75 India 23.25
Fung et al. (2007)76 India 101.88
Dandona et al. (2008)77 India 24.02
Kumar et al. (2009)78 India 2.78 2.78
Chandrashekar et al. (2010)79 India 185.06d
Dandona et al. (2010)56 India 35.81 8.64 2.78
Siregar et al. (2011)80 Indonesia 40.90 68.17 24.12
Eastern Europe and central Asia
Kumaranayake et al. (2004)81 Belarus 70.29
Vickerman et al. (2006)82 Ukraine 5.36

US$, United States dollars.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Adjusted to the dollar values for the year 2011.

C US$ 9.16 per person reached, if the costs of supervision are excluded.

d US$ 149.38 per person receiving sexually-transmitted-infection services.

Table 7. Summary of selected mean unit costs of voluntary medical male circumcision.

Region and referencea Country Cost per circumcision performed, US$b
Africa – eastern and southern
Futures Institute83 and Kioko, personal communication (2010) Kenya 36.26c
Binagwaho et al. (2010)84 Rwanda 15.67d or 61.65e
Martin et al. (2007)85 Lesotho 60.84
USAID (2010)86 South Africa 70.48
USAID (2010)87 Uganda 20.71
Futures Institute83 and Chiwevu, personal communication (2010) Zambia 74.10
USAID (2010)88 Zimbabwe 66.18

US$, United States dollars, USAID, United States Agency for International Development.

a The region shown is one defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Adjusted to the dollar values for the year 2011.

c Mean value for the static and outreach sites.

d For a hypothetical cohort of 150 000 neonates.

e For a hypothetical cohort of 150 000 adolescents and adults.

Table 8. Summary of selected mean unit costs of the elimination of mother-to-child transmission of human immunodeficiency virus.

Region and referencea Country Cost, US$b
Per visit Per patient-year Per pregnant women Per mother–neonate pair Per person counselledc Per person tested
Africa – eastern and southern            
Orlando et al. (2010)89 Malawi     395.17      
Desmond et al. (2004)90 South Africa   567.36d     96.22 103.82
Bratt et al. (2011)37 Zambia 42.23d          
Asia and Pacific            
Dandona et al. (2008)91 India       257.52    

US$, United States dollars.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Adjusted to the dollar values for the year 2011.

c Both pre- and post-testing.

d Including costs of prenatal and postnatal visits.

Table 9. Studies on antiretroviral therapy included in the systematic review.

Region and referencea Last year of data collection Country Location No. and type of sites Description of intervention or model Empirical or modelled Costing scope Costing method Mean unit cost(s), US$ (range)b
Africa – eastern and southern
Hounton (2008)38 2006 Benin Urban 1 public university hospital Set in the outpatient treatment centre of the National University Hospital. The centre, which was solely devoted to care and support for people living with HIV, received technical support from an NGO. HIV care consisted of physical examination, laboratory checks (CD4 counts, blood cell counts and blood biochemistry) and counselling four times a year and monthly procurement of ART and OI drugs Empirical (primary cost data from facility) and modelled (over 10 years for 12 outpatient treatment centres and 48 peripheral treatment centres) Economic, full, societal perspective Micro-costing, top-down 1348 (1293–1403)
Renaud (2009)39 2007 Burundi Urban 1 primary health-care centre run by NGO The Bujumbura health centre of the Society for Women against AIDS in Africa provided care only to people living with HIV. ART was delivered to 668 people in 2007, making it the fourth largest ART clinic in Burundi. HIV care included outpatient visits, a laboratory and pharmacy, VCT, adherence counselling and psychosocial and food support Mostly empirical (primary cost and patient-use data; secondary data used for drug prices, CD4 counts, assays of viral load and hospital costs) Economic, full, provider perspective Combined top-down and bottom-up micro-costing 1017 (795–1409)
Kombe (2005)22 2005 Ethiopia National 6 public hospitals Set in government-certified hospitals that provided ART, eMTCT and VCT services as stand-alone activities (national guidelines stipulated that these services should be fully integrated in hospital care). Costing of ART services included costs of ARV drugs and clinical monitoring but excluded treatment of OIs Empirical (primary cost data, with estimates of patient use based on experts’ opinions and protocols) Financial, incremental, provider perspective Gross costing, bottom-up 812
Bikilla (2009)21 2006 Ethiopia Rural 1 HIV clinic within a regional public hospital The HIV unit in the Arba Minch Hospital provided free first-line ART on an outpatient basis, although AIDS patients with severe clinical manifestations could be admitted. CBC counts and clinical chemistry were standard laboratory tests for HIV patients and CD4 counts were introduced in 2005. Final services in relation to HIV care included outpatient consultations, laboratory tests, imaging, drug provision and inpatient services for both non-ART and ART patients Empirical (data on primary costs and use of inpatient and outpatient services) Economic, full, provider perspective Combined bottom-up and top-down micro-costing (with ingredient approach) 142 (112–178) for non-ART, 308 (301–318) for ART
Marseille (2011)23 2009 Ethiopia Urban 14 ART-delivery sites in three provinces The management of ART cases at risk of poor adherence was investigated in 14 sites supported by the I-TECH collaboration between the Universities of Washington and California. The management consisted of adherence counselling and support, health education, peer support and referral of clients to CBOs who were equipped to address specific barriers to adherence (such as malnutrition, substance abuse and material needs for clothing, rent and food) Empirical Financial, incremental, provider perspective (included regional and national overhead costs but excluded costs of ARV drugs) Micro-costing, bottom-up 148 (41–591)
Cleary (2007)24 2006 Lesotho Rural 1 public hospital and 14 primary health centres MSF and the MoH implemented a joint pilot programme with Scott Hospital Health Service Area to decentralize free HIV/AIDS care and treatment, including ART, to the primary health-care level. The programme provided comprehensive HIV services – including eMTCT services and HIV DNA testing by PCR – for early diagnosis of HIV in infants, HIV care (including management of opportunistic infections and other HIV-related conditions), and ART Empirical (primary cost data on service utilization and programme-level costs, modelling of ARV and laboratory costs based on utilization according to clinical protocols) Financial, partial, provider perspective Micro-costing, bottom-up 18 (11–24) for pre-ART, 1093 (214–1587) for ART
Kombe (2004)40 2004 Nigeria National 5 public specialized and teaching hospitals providing ART The provision of ART to HIV patients is a major component of Nigeria’s National HIV/AIDS Emergency Action Plan. The study determined the costs of ART (including ARV drugs and clinical monitoring but excluding treatment of opportunistic infections) in a hospital setting Empirical (primary and secondary data) Financial, incremental, provider perspective Gross costing, bottom-up 879
Partners for Health Reformplus (2004)41 2004 Nigeria National 15 ART clinic and ART centres and 51 private clinics and faith-based and NGO programmes Assessment of HIV treatment commissioned by USAID and Nigeria Mission. Aims were to understand current status, challenges and costs of providing HIV/AIDS services in public sector (federal government programme) and private sector (corporations, private clinics, faith-based and NGO programmes) Empirical (secondary data) Financial, provider perspective Bottom-up 1081 in the public sector, 2680 in the private
Aliyu (2012)42 2010 Nigeria Urban and rural 7 secondary public hospitals and 1 tertiary (4 urban and 4 rural) HIV services assumed to be integrated. A typical comprehensive site provided a package of HIV testing, prevention, treatment, care and support. The delivery points for ART and HIV testing and counselling were used as cost centres because each was an operational unit that contributed towards the overall cost of HIV/AIDS services in the study hospitals Empirical Financial, provider perspective, costing analysis Micro-costing, top-down 211 overall; 206 in secondary hospitals, 341 in tertiary, 230 in urban, 203 in rural
Cleary (2006)25 2002 South Africa Periurban 3 public HIV clinics HIV clinics, within existing public-sector clinics, provided ART, treatment and prophylaxis of HIV-related and opportunistic infections and events, and counselling and support groups for HIV-positive people. Acute infections were managed at the clinics but severely ill patients were referred to secondary and tertiary hospitals. Suspected TB cases were referred. Both non-ART (actually pre-ART) and ART patients were considered Empirical (primary cost data for HIV-clinic services and secondary data for part of the cost of TB services and inpatient care at referral hospitals) Economic, full, provider perspective Micro-costing, bottom-up 945 (713–1176) for non-ART, 1483 (831–2696) for ART
Deghaye (2006)26 2004 South Africa Urban and periurban 2 state-subsidized hospitals The hospitals provided HAART to their staff members through preferential access or as part of their service package, following national guidelines. HIV testing, counselling and treatment were done on a one-to-one basis with the staff doctor – to preserve staff confidentiality and encourage staff to take up HIV treatment Empirical (primary cost and patient-use data were collected) Financial and economic, full and incremental, provider perspective Micro-costing, bottom-up 1326 (1045–1607)
Harling (2007)28 2004 South Africa Periurban 1 ART clinic run by NGO As above Empirical As above Micro-costing, bottom-up 2153 (1626–2963)
Kevany (2009)31 2005 South Africa Periurban 1 public hospital Set in a secondary hospital with an ARV referral unit designed as a referral service for complex cases from the hospital’s ARV clinic and five local primary ART clinics. The unit provided specialist-directed investigation and treatment, including comprehensive outpatient care and consultation services to patients in the hospital’s medical wards Empirical (primary cost and resource-use data, with pharmaceutical and procedure costs sourced from government’s drug price list and fee schedule) Economic, incremental, provider perspective Combined bottom-up micro-costing (patient-specific costs) and top-down micro-costing (shared costs) 2782
Martinson (2009)32 2005 South Africa Urban One HIV clinic The perinatal HIV research unit is a research organization located on the campus of the Chris Hani Baragwanath Hospital, but is not administratively integrated within the hospital (no shared costs). It provides a free-of charge ART service. Patients are referred from other programmes in the perinatal HIV research unit or self-refer and are started on ART based on national treatment guidelines.
a) Pre-ART visits include baseline CD4, viral load, liver function and haematology tests and symptom-based screening for TB.
b) ART: CD4 cell count and viral load are measured every six months, haematology and liver function tests every three months
Empirical – primary
cost and patient
service use data
Economic
Full costing
Provider
perspective
Combination
of top-down
and bottom-up
1207 (893–1521) for pre-ART
2415 (1849–2981) for ART
Harling (2007)27 2006 South Africa Periurban 1 ART clinic run by NGO Clinic based at the Gugulethu Day Hospital and jointly run by the Desmond Tutu HIV Centre, the charity Crusaid and the provincial government of the Western Cape. Eligibility criteria for the clinic included a CD4 count of < 200 cells/ml or a history of an AIDS-defining illness. Counsellors were employed from the local community and responsible for up to 50 patients each, providing pre-treatment counselling, group education on living on ART, home visits to monitor adherence and ongoing treatment support Empirical Financial, full, provider perspective Combined top-down micro-costing and bottom-up gross costing 546 (518–573)
Vella (2008)30 2006 South Africa National 32 public ART delivery clinics ART delivery sites had the following profiles:
a) Part-time doctor and part-time senior professional nurse with less than 200 new patients per doctor per year;
b) Same staff as above but with 200 or more new patients per doctor per year;
c) Full-time doctor and senior professional nurse with less than 200 new patients per doctor per year; and
d) Same staff as above but with 200 or more new patients per doctor per year
Empirical cost data
from site financial
and resource use
records and registers
Financial
partial cost
(excluding costs of other health services and hospitalisation) Provider
perspective
Top-down
micro-costing
207
Rosen (2008)29 2007 South Africa 1) Urban
2) Urban
3) Rural
4) Periurban
1) One public
referral hospital
2) One private
general
practitioners
3) One NGO
AIDS clinic
4) One NGO primary care
clinic
Site 1 is a large academic and referral hospital. Its HIV clinic has an associated research unit and donor financial support.
Site 2 is a donor-funded, NGO managed programme that contracts private general practitioners to provide ART to indigent patients who would otherwise rely on the public sector. Drug and laboratory regimens, clinic visit schedules and reimbursement conditions are set by the NGO.
Site 3 provides ART as well as other facility and community-based HIV⁄AIDS services. It is unusual in being a dedicated, stand-alone HIV/AIDS clinic.
Site 4 serves informal settlements on the edge of a large city (Entirely donor funded and has an integrated HIV clinic providing ART and other HIV⁄AIDS services). Each model included a different mix of VCT, palliative care, OI treatment, pre-ART, ART, monitoring visits, laboratory tests and adherence counselling
Empirical – primary
cost and patient
service use data
Economic full costing
Provider
perspective
Bottom-up micro-costing 843 for urban public referral hospital
999 for urban private general practitioners
1039 for rural NGO AIDS clinic
1255 for periurban NGO PC clinic
Long (2010)33 2007 South Africa Urban 1 public HIV clinic Set in large outpatient HIV clinic that was in an academic referral hospital and funded by the provincial DoH and USAID. The resource use of adult patients who had begun second-line therapy was considered, including drugs, laboratory tests, outpatient visits to the clinic and a pharmacy, infrastructure and other fixed costs Empirical (primary cost and resource-use data) Economic, full, provider perspective Combined top-down (shared fixed cost) and bottom-up micro-costing (direct costs) 1088
Long (2011)34 2009 South Africa Urban 1 treatment-initiation site and 1 down-referral site Study designed to evaluate the implications of a down-referral strategy for treatment outcomes and costs Empirical Financial, provider perspective, cost–effectiveness analysis Macro-costing approach (total site-level costs were estimated for each patient type) 566 at treatment-initiation site, 505 at down-referral site
Babigumira (2009)35 2008c Uganda National (primary data from rural settings) 2 public clinics (for primary cost data) National provision of ART and related care through facility-, mobile-clinic- or home-based programmes Secondary data used for cost of ARVs, empirical primary data for indirect recurrent costs of facility- and mobile-clinic-based care Financial, full and incremental, provider perspective Combined bottom-up and top-down 337, 502 and 738 for facility-, mobile-clinic- and home-based programmes, respectively
Jaffar (2009)36 2009 Uganda Urban, rural and periurban 1 clinic run by NGO Large AIDS Support Organisation clinic offered counselling and social and clinical services to people with HIV, based on national guidelines. Eligible patients were prepared for therapy by staff during three clinic visits, which were usually spread over 4 weeks. Information and counselling were provided in groups and in one-to-one sessions. Participants were given drugs for 28 days of treatment and issued with a pill box and a “buffer” supply for 2 days. Patients were encouraged to identify a “medicine companion” to provide adherence support. During a trial, after they had initiated ART, 1453 patients were randomly assigned either to home-based HIV care (with lay workers delivering ART and monitoring patients) or facility-based HIV counselling, ART and monitoring visits Empirical (primary cost data from organizational accounts) Economic, full, societal perspective (including supervision costs) Top-down for provider costs and bottom-up for patient costs 832 for home-based care, 879 for facility-based
Bratt (2011)37 2009 Zambia Urban and rural 12 facilities supported by the Zambian Prevention, Care and Treatment Partnership. From these, 6 hospitals and 4 health centres provided human immune-deficiency virus counselling and testing services.
Services were integrated
Initiating, improving and scaling up eMTCT, HCT and clinical-care services, for people living with HIV, during Antenatal Care and Perinatal Care in urban and rural settings Empirical (resource use estimated from primary data) Economic, full, provider perspective
(including upstream supervision and support costs)
Combined top-down and bottom-up 362 for hospital-based sites d
358 for health-centre based sitesd
Asia and Pacific
John (2006)44 2005 India Urban 1 NGO site The Freedom Foundation centre provides care and support for people living with HIV, including HAART and laboratory monitoring. The NGO receives government grants and in-kind support, including essential and TB drugs, NGO staff remuneration, food for inpatients and one-time infrastructure support. Other donors fund the majority of the HIV treatment programme and most clients must pay for their own HAART (medicines and laboratory monitoring). Costs were estimated for patients who were eligible for HAART but could not afford it (who only had their opportunistic infections managed) and patients who were on HAART Empirical (primary data) Financial, full, NGO perspective (system costs, ARV costs and other costs borne by government excluded) Micro-costing, bottom-up (50 patients) 356 for non-HAART patients, 37 for HAART
Gupta (2009)43 2006 India Urban 7 multi-specialty public hospitals In India, the rollout of the National Free ART programme began in 2004 and covered three groups: pregnant women, children aged < 15 years and AIDS patients who sought treatment in large public-sector hospitals. The rollout started in six high-prevalence states and the capital. It was put in place in government hospitals and medical colleges and consisted of a comprehensive range of services (ART, treatment of opportunistic infections, diagnostic tests and outpatient and inpatient services) Empirical (primary data) Financial, full, programme perspective (excluded capital costs) Micro-costing, top-down 380 (287–545)
Kitajima (2003)45 2002 Thailand Rural 2 hospitals The Khon Kaen Regional Hospital was a referral hospital for both the community hospitals in the province and general hospitals in neighbouring provinces. It had a follow-up clinic for HIV-positive patients and provided admission services to them. The North-east Regional Infectious Hospital was a specialized hospital for infectious diseases, focusing on 19 provinces in north-eastern Thailand. It had an HIV clinic and an inpatient ward for HIV-positive patients Empirical (primary cost and resource- use data plus secondary data for costs of routine outpatient and inpatient service) and modelling (of province-wide and annual unit costs) Financial (assumed), full, provider perspective Micro-costing, bottom-up 4749
Caribbean
Koenig (2008)46 2004 Haiti Urban 1 HIV clinic run by NGO The Haitian Study Group for Kaposi’s Sarcoma and Opportunistic Infections, which was formed in 1982, provided clinical services and training and conducted research on HIV/AIDS. Specifically, it provided free HIV counselling, testing, STI screening, TB evaluation, ART, laboratory tests, adherence counselling (patients were given pre-paid telephone cards to contact clinic staff), management of opportunistic infections and nutritional supplementation Empirical (primary data for cohort of 218 patients) Economic, full, societal perspective Micro-costing, bottom-up 1137
Latin America
Marques (2007)47 2001 Brazil Urban 1 public university teaching hospital Set in a children’s institute that provided clinical services for children exposed to – or infected with HIV – in ambulatory, day-hospital and infirmary units Empirical (primary data from cohort of 140 HIV-infected patients) Financial, full, provider perspective Micro-costing, bottom-up 5875 (2060–10 732)
Bautista (2003)49 and Bautista-Arredondo (2008)92 2001 Mexico Urban 11 public facilities, including specialized tertiary care, secondary care and specialized HIV outpatient clinics Mexico’s five national social-security institutions offered free HIV/AIDS care from specialists in tertiary hospitals and/or secondary hospitals that had specialists. The MoH ran a national programme to cover HIV care and treatment for the uninsured. The costs of HIV/AIDS treatment (including those related to drugs for inpatient and outpatient care, laboratory tests and surgical procedures) for the MoH, the social-security institutions and the National Institute of Health were estimated Empirical (primary data, for cohort of 1003 HIV-positive patients) Financial, full, provider perspective Micro-costing, bottom-up (medication and laboratory costs) 835 (256–1356) for pre-HAART, 4097 (3729–4820) for HAART
Contreras-Hernandez (2010)50 2005 Mexico Urban 9 hospitals Hospital care for HIV/AIDS patients consisted of routine HIV care (for both inpatients and outpatients), ART, tropism testing, treatment of adverse events associated with ART, acute and prophylactic treatment of opportunistic infections, CD4 cell counts, HIV test, and palliative care preceding death for both HIV and opportunistic infections Empirical (data on hospital unit costs, plus primary resource-use, data based on cohort of 637 patients treated for HIV in one hospital) and modelled (patient-level costs) Financial, partial (drug costs only), provider perspective Micro-costing, bottom-up 2007 (1649–2467) for empirical data, 13 389 (5180–28 494) for modelled
Aracena-Genao (2008)48 2006 Mexico Urban 1 public hospital Ambulatory HIV services included outpatient visits, ART drugs, medications used to treat or prevent opportunistic infections and laboratory diagnostic and monitoring tests. Hospitalization activities including inpatient days, drugs, laboratory tests and radiological or surgical procedures. Empirical (primary cost data) and modelling (for dynamic cohort of 797 HIV patients in care between 1982 and 2006) Financial, full, provider perspective Micro-costing, bottom-up 8536 for non-ART patients, 9407 (7145–13 011) for ART
North Africa and Middle East
Loubiere (2008)51 2002 Morocco Urban 1 public hospital Set in the Infectious Diseases Unit in the Ibn Rochd Hospital – the major facility treating HIV-1 patients in Morocco – which served indigent patients referred from primary health-care facilities Empirical (primary data from a cohort of 286 HIV-positive patients) Financial, full, provider perspective, intention-to-treat analysis Micro-costing, bottom-up 416 (305–664) for non-HAART, 1156 (1125–1177) for HAART
Global
Menzies (2011)20 2007 Botswana, Ethiopia, Nigeria, Uganda and Viet Nam National 7 (Uganda) or 9 outpatient clinics per country Costs estimated for pre-ART (supportive care, regular clinical and laboratory monitoring) and ART (outpatient first- and second-line regimens), regular clinical and laboratory monitoring, prophylaxis against opportunistic infections, treatment for HIV-related conditions, nutritional support and adherence and other related interventions Empirical Financial and economic, full, provider perspective Micro-costing, top-down 200 for pre-ART and 514 (344–751) for ART in Botswana, 154 for pre-ART and 842 (660–1048) for ART in Ethiopia, 266 for pre-ART and1263 (884–1818) for ART in Nigeria, 146 for pre-ART and 736 (384–993) for ART in Uganda, 177 for pre-ART and 898 (729–986) for ART in Viet Nam
Menzies (2012)93 2007 Botswana, Ethiopia, Nigeria, Uganda and Viet Nam National 7 (Uganda) or 9 outpatient clinics per country Costs estimated for pre-ART (supportive care, regular clinical and laboratory monitoring) and ART (outpatient first- and second-line regimens), regular clinical and laboratory monitoring, prophylaxis against opportunistic infections, treatment for HIV-related conditions, nutritional support and adherence and other related interventions Empirical, assessed proximal determinant of per-patient costs Financial and economic, full, provider perspective Micro-costing, top-down See Menzies et al. (2011)20

AIDS: acquired immunodeficiency syndrome; ART: antiretroviral therapy; ARV: antiretroviral; CBC: complete blood-cell; CBO: community based organization; CD4: cluster of differentiation 4; DNA: deoxyribonucleic acid; DoH: Department of Health; eMTCT: elimination of mother-to-child transmission; HAART; highly-active antiretroviral therapy; HCT: human immunodeficiency virus counselling and testing; HIV: human immunodeficiency virus; MoH: Ministry of Health; MSF: Médecins Sans Frontières; NGO: nongovernmental organization; OI: opportunistic infection; PC: primary health care; PCR: polymerase chain reaction; STI: sexually transmitted infection; TB: tuberculosis; US$: United States dollars; USAID: United States Agency for International Development; VCT: voluntary counselling and testing.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS. For brevity, only the first author of each publication is shown. The publications generally provide much more detail about costings, the assumptions made in evaluating costs and the drug regimens involved than can be neatly summarized here.

b Costs are shown per patient-year. They have been adjusted to the dollar values for the year 2011 and then rounded to integer values. They are financial unless indicated otherwise.

c Although the published results of this study do not state when data were collected, the published costs are given as values for the year shown here.

d Mean for first year ART across all drug regimens.

Table 10. Study on behaviour-change communications included in the systematic review.

Region and referencea Last year of data collection Country Location No. and type of sites Description of interventions Empirical or modelled Costing scope Costing method Mean unit cost(s), US$ (range)b
Africa – western and central
Hsu et al. (2013)52 2009 Benin National 29 communes in 7 departments across Benin. Services assumed to be integrated Interventions to promote safer sexual behaviour and the systematic use of condomsc Empirical Economic, provider perspective, costing analysis Capital and recurrent cost framework 26, 40, 19, 5 and 2 – per person reached – using billboards, peer education, magazines, radio and public outreach events, respectively; 23, 26 and 32 – per person reporting systematic condom use –using magazines, radio and public outreach events, respectively

US$: United States dollars.

a The region shown is one defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Costs have been adjusted to the dollar values for the year 2011 and then rounded to integer values.

c Interventions included billboards (56 billboard sides featuring messages regarding the prevention of human immunodeficiency virus (HIV) and adverts for condoms displayed for a period of 6 months in major cities and along highways), peer education (one-to-one or small group discussions held 5–10 times a month, led by one of 200 trained sex workers or youth peer educators, designed to raise awareness of prevention and transmission of HIV and to encourage behaviour change), a magazine (youth-oriented magazine issued about six times a year, of approximately 15 pages, covering sexual and reproductive health topics such as delaying the onset of sexual activity, fidelity, contraception and other means to prevent transmission, and communicating with partners and parents), radio broadcasts by 10 contracted radio stations (150 short broadcasts per month, each of about 30 s, on HIV prevention and transmission per month, plus themed talk show, of about 45 min, broadcast about twice a week and targeting youth and covering a variety of sexual and reproductive health topics) and public outreach events (held in local communities, hosted by a network of 16 contracted nongovernmental organizations, designed to disseminate messages via theatrical sketches, condom-use demonstrations and the projection of short videos)

Table 11. Studies on condom distribution included in the systematic review.

Region and referencea Last year of data collection Country Location No and types of sites Description of intervention Empirical or modelled Costing scope Costing method Mean unit cost(s), US$ (range)b
Africa – eastern and southern
Terris-Prestholt (2006)54 2001 Uganda Rural 18 parishes with an approximate combined population of 96 000. Services were integrated Between 1994 and mid-2000, a range of HIV-prevention interventions was evaluated as part of the Masaka intervention trial. The aim of this three-armed randomized controlled trial was to measure and compare the impact of IEC alone and IEC with STI management on reducing the incidence of HIV and other STIs at community level. All arms received VCT and the social marketing of condoms. The condom promoter distributed condoms monthly to established commercial outlets in all 18 parishes, for resale. Costings were provided for 1 495 570 condoms distributed over 4 years (1996–1999) Empirical (primary data) Economic, incremental, provider perspective Step-down 0.12 (0.10–0.16) per condom soldc
Terris-Prestholt (2006)55 2001 United Republic of Tanzania Rural 10 communities, each formed of 5 or 6 villages. Overall,186 school-years, 54 health-facility participation years and 30 community years were costed. Services were integrated The Mema kwa Vijana intervention trial was implemented by an international NGO and designed to estimate the incremental impact of an intensively developed youth intervention. The intervention had four main components: ASRH education for 3 years of primary school (in-school), community-mobilization activities and youth-friendly services to improve youth access to sexual health services, and community-based peer condom promotion and distribution. Results were provided for 3 years of intervention implementation (1999–2001) Empirical (primary data) Economic and financial, incremental and full, provider perspective Combination of top-down and bottom-up 1.87 (financial) and 1.94 (economic) per condom sold
Asia and Pacific
Dandona (2010)56 2006 India National 1 HIV-prevention intervention programme serving 190 599 people over 4 years One public-funded HIV-prevention programme based on condom promotion and targeted at groups at high risk of HIV infection Empirical (primary data) Economic, provider perspective Combination of top-down and bottom-up 1.54 per person reached
Global
Söderlund (1993)53 1986–1992 Bolivia, Brazil, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Dominican Republic, Ecuador, Ghana, Indonesia, Mexico, Morocco, Uganda, Zimbabwe National Not available Case studies of operating programmes designed to promote safer sexual behaviours and condom use, either by person-to-person education or by the social marketing of condoms Empirical Financial, provider perspective Capital and recurrent cost framework 1.12, 0.54, 0.34 and 0.16 per condom distributed in Brazil, Cameroon, Uganda and Zimbabwe, respectively; 0.72, 0.24, 0.18, 0.21, 0.29, 0.13, 0.07, 0.41, 0.81 and 0.97 per condom sold in Bolivia, Côte d’Ivoire, Democratic Republic of the Congo, Dominican Republic, Ecuador, Ghana, Indonesia, Mexico, Morocco and Zimbabwe, respectively

ASRH: adolescent sexual and reproductive health; HIV: human immunodeficiency virus; IEC: information, education and communication; NGO: nongovernmental organization; STI: sexually transmitted infection; US$: United States dollars; VCT: voluntary counselling and testing.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS. For brevity, only the first author of each publication is shown. The publications generally provide much more detail about costings and the assumptions made in evaluating costs than can be neatly summarized here.

b Costs have been adjusted to the dollar values for the year 2011 and are financial unless indicated otherwise.

c The range shows the variation in annual values.

Table 12. Studies on human immunodeficiency virus counselling and testing included in the systematic review.

Region and referencea Last year of data collection Country Location No. and type of sites Description of interventions and models Empirical or modelled Costing scope Costing method Mean unit cost(s), US$ (range)b
Africa – eastern and southern
Kombe (2005)22 2005c Ethiopia National 6 hospitals Pre-test counselling, drawing blood, testing and post-test counselling Empirical Financial, incremental, provider perspective (costs of labour, training and supplies included) Bottom-up 5 per client per episode
Twahir (1996)57 1994 Kenya Urban 2 clinics A case study in which the process of applying an integrated model (in which STI and HIV/AIDS services were integrated with existing services for maternal and child health and family planning) was compared with that of applying a non-integrated model Empirical Financial, incremental, provider perspective Combined top-down and bottom-up 12 and 18 per client-visit in the integrated and non-integrated models, respectively
Forsythe (2002)59 1999 Kenya Rural and urban 3 health centres Health centres provided rapid, same-day testing. NGO-paid counsellors drew blood and then performed an initial HIV test using the Immunocomb test kit. Positive results were confirmed with the Capillus test Empirical Full economic and incremental financial, provider perspective (head-office and research costs included in full costs) Top-down 62 (economic) and 21 (financial) per VCT client
John (2008)60 2003 Kenya Urban 1 ANC clinic HCT included health education, testing and pre- and post-test counselling. Women attending their first antenatal visit were provided information, as a group, on HIV-1 infection and eMTCT interventions, and were then asked to return in 7 days, with their partners, for HIV-1 counselling and testing. Following pre-test counselling, blood was collected for rapid HIV-1 testing on site and results were disclosed on the same day. Two models were investigated: standard VCT in an ANC clinic and couple counselling for eMTCT Empirical Financial, incremental, provider perspective (upstream system costs and fixed costs such as rental and utilities excluded) Bottom-up 7·(6–9) and7 (6–9) per woman in ANC and the standard VCT and couple counselling, respectively
Negin (2009)62 2005c Kenya Rural 1 local community-based organization A 3-month curriculum for training in HIV counselling and testing. Counsellors were registered by the Government of Kenya’s National AIDS and STI Control Programme. Rapid ELISA-based testing for HIV antibodies was conducted. Home-based VCT was offered to all interested household members. Tests were conducted independently for each individual except for couples who requested to be tested together. The post-test counselling that was provided depended on the results of the HIV tests Empirical Financial, provider perspective Bottom-up 7 per person tested
Grabbe (2010)63 2006 Kenya National 6 stand-alone and 6 mobile sites Following standardized procedures, the HCT delivered by trained counsellors was free, voluntary and confidential. Finger-prick samples of blood were collected and checked for antibodies to HIV in rapid tests. Counsellors, who delivered pre-test counselling to individuals, couples, families or groups, discussed basic HIV/AIDS information, explained the HIV testing process, and discussed the clients’ risk behaviours. Immediately following rapid testing, post-test counselling was conducted with all clients to explain test results, develop personalized prevention strategies, discuss partner testing and disclosure, and offer appropriate referrals. HCT provided at free-standing, fixed centres (mostly urban or periurban and not attached to a health facility) or at mobile sites (semi-mobile containers or a fully mobile truck) Empirical Financial, full and incremental, provider perspective (upstream system costs excluded) Top-down 29 (fixed sites) and 15 (mobile sites) per HCT client
Liambila (2008)61 2007 Kenya Rural, urban and periurban 23 health facilities Two models of integrating HCT into FP services were pilot tested. The “testing” model was implemented in Nyeri district (an area with relatively few VCT sites). In this model, FP clients were educated about HIV prevention generally and HCT in particular and were then offered HCT during the same consultation, by the FP provider. The “referral” model was implemented in Thika district (an area with good accessibility to VCT services). In this model, FP clients were educated about HCT and those interested were referred to a specialized HCT service (within the same facility, at another health facility or at a stand-alone HCT centre) Empirical Financial, incremental, provider perspective Combined top-down and bottom-up 10 and 33 per client tested in the testing and referral models, respectively
Obure (2012)64 2009 Kenya and Swaziland Urban and rural 28 public and private not-for-profit hospitals, health centres and SRH clinics (20 sites in Kenya, 8 in Swaziland) HCT was provider-initiated (incorporated into routine health care – including general primary care, maternal and child health care, care for STIs and inpatient services – with pre- and post-test counselling provided by a nurse and testing conducted either by the same nurse or by a laboratory technician or lay counsellor, and counselling sometimes in groups) or client-initiated (through VCT centres, with counselling and testing provided by a lay counsellor or a nurse and generally involving one-to-one or couples counselling) Empirical Financial and economic, full, provider perspective (upstream system costs excluded) Combined top-down and bottom-up 8 (5–16) and 12 (7–20) per person tested in the provider- and client-initiated HCT, respectively
Sweat (2000)58 1998 Kenya and United Republic of Tanzania Urban 1 free-standing VCT clinic in each country Clinic-based VCT provided according to the CDC’s client-centred HIV-1 counselling model. Included personalized risk assessment and development of personalized risk-reduction plans. Serum samples tested for HIV-1 in commercial ELISA. All positive samples confirmed with a second ELISA. Inconclusive test results confirmed by western blot or immunofluorescence assay. Clients asked to return for results and counselling after 2 weeks. Additional counselling for participants who did not agree to be tested. Condom demonstration and role play provided as part of HCT. Demand created through posters, flyers and short, weekly, radio commercials Empirical Economic, incremental, provider perspective Top-down 35 (23–50) and 38 (22–63) per client in Kenya and United Republic of Tanzania, respectively
McMennamin (2007)94 2007 Rwanda Rural and periurban 5 rural health centres and 1 periurban A costing study to inform performance-based financing and contracting for HIV services in Rwanda, including unit costs for eMTCT, VCT and OI services for 2005 Empirical Financial, provider perspective Bottom-up 5 per consultation
Hausler (2006)66 2002 South Africa Urban and periurban 12 community health centres, 1 primary health-care clinic and 1 STI clinic The costs and cost–effectiveness of the ProTEST package of TB and HIV interventions were investigated in health-care facilities in Cape Town Empirical Economic and financial, provider perspective Ingredients approach 3 (2–4) and 2 (1–3) per person pre- and post-test counselled, respectively
McConnel (2005)65 2003 South Africa Periurban 1 church-based, non-profit organization Within a 2-hours period, clients received pre-test counselling, an HIV test and test results in a post-test counselling session. The results of initial tests (Efoora) were confirmed with another rapid test (Abbott Determine), eliminating expenditure on laboratory-based testing Empirical Financial and economic, provider perspective Combined top-down and bottom-up 72 (34–159) per client (financial) and 114 (49–255) (economic)
Terris-Prestholt (2006)54 1999 Uganda Rural 18 parishes with community-based interventions A three-armed randomized controlled trial in 18 parishes of the impact of the following HIV-prevention interventions: IEC (both community- and school-based); strengthened STI services; social marketing of condoms; and VCT. VCT consisted of two trained counsellors visiting communities, to provide VCT services, twice per month. From 1996–1998, HIV testing was done centrally and clients were required to return for results after 2 weeks. In 1999, rapid tests were introduced, and results were provided to clients at the same visit Empirical Economic, full, provider perspective (central support costs included) Top-down 35 (22–46) per client receiving post-test counselling
Tumwesigye (2010)68 2005 Uganda Rural Homes Home-based HCT was provided by 29 outreach teams, each consisting of a laboratory assistant and a counsellor offering HIV education and HCT. Participants could choose to be tested and receive results as individuals or as couples. In addition,170 resident parish mobilizers and village chairmen mobilized communities, supported the outreach teams, provided follow-up post-test support, encouraged the formation of parish-based HIV post-test clubs and referred those diagnosed with HIV infection to relevant service organizations Empirical Financial, provider perspective Top-down 8 per person reached with bundled services
Menzies (2009)67 2009 Uganda National 4 models In each model, HIV testing was provided in a single session using a serial HIV rapid-test algorithm. Pre-test and post-test counselling were provided, covering basic HIV/AIDS information, the testing process, risk-reduction strategies, the interpretation of positive or negative test results, partner communication and disclosure, and voluntary consent. Referral for HIV care and treatment were provided for clients found HIV-positive. Testing was free, voluntary and private, and clients were encouraged to be tested with their partners. The four models investigated were “stand-alone” (client-initiated HCT at free-standing centres), “hospital-based” (provider-initiated HCT via an opt-out approach for inpatients and outpatients), “door-to-door” (home-based, provider-initiated HCT via mobile teams) and “household-member” (same as door-to-door but targeting members of households of HIV-positive patients) Empirical Economic, full, provider perspective Top-down 21, 13, 9 and 15 per client in the standalone, hospital-based, door-to-door and household-member models, respectively
Bratt (2011)37 2009 Zambia Rural and urban 12 facilities supported by the Zambian Prevention, Care and Treatment Partnership. From these 5 hospitals and 6 health centres provided human immune-deficiency virus counselling and testing services. Services were integrated Initiating, improving and scaling up eMTCT, HCT and clinical-care services, for people living with HIV, during Antenatal Care and Perinatal Care in urban and rural settings Empirical (resource use estimated from primary data) Economic, full, provider perspective
(costs of upstream supervision and support included)
Combined top-down and bottom-up 15 (9–22) and 22 (15–31) per HCT outpatient visit in the hospitals and health centres, respectively
Africa – western and central
Kombe (2004)40 2004c Nigeria National 5 ART sites A programme of VCT in which initial testing was based on an ELISA and positive results were confirmed with an ELISA, a Genie2 rapid test or an Abbott Determine rapid test Empirical (secondary data on prices of test kits) Financial, incremental, provider perspective (upstream costs excluded) Bottom-up 5 per HIV-negative client and 13 per HIV-positive
Aliyu (2012)42 2010 Nigeria Urban and rural 7 secondary public hospitals and 1 tertiary (4 urban and 4 rural). Services assumed to be integrated A typical comprehensive site provided a package of HIV testing, prevention, treatment, care and support. HCT and ART service delivery points were used as cost centres for this study because each was an operational unit, contributing towards the overall cost of HIV/AIDs services in the study facilities Empirical Financial, provider perspective, costing analysis Top down 8 per client (6, 19, 6 and 10 in the secondary, tertiary, urban and rural hospitals, respectively)
Asia and Pacific
Dandona (2005)69 2003 India National 17 VCT centres The study was conducted as part of a larger, multicountry effort to study the cost and efficiency of HIV prevention. Clients received VCT at VCT centres, up to post-test counselling. The VCT included the provisions of condoms and behaviour-change communications. HIV infection was initially investigated with a rapid test kit and only considered confirmed after two further tests had given positive results. The final result was certified by a medical officer and communicated to the client on the day after sample collection. All but the poorest clients were charged a nominal fee Empirical Economic, incremental, provider perspective (upstream system costs excluded) Top-down 10 (4–21) per client receiving post-test counselling
Das (2007)70 2006 India Rural 1 integrated rural health clinic The Child in Need Institute decided to integrate its reproductive health clinic with its centre for voluntary confidential HIV counselling and testing. The integrated clinic continued to provide curative services for reproductive-tract infections and STI, preventive services such as family planning, condom distribution and counselling on HIV risk behaviours, as well as voluntary confidential HCT. Blood samples were sent to a government laboratory for testing. Registration and screening fees were charged to clients. Outreach services included outreach meetings and the distribution of posters and leaflets – to villages within a 20-km radius of the clinic – that described the integrated clinic and provided information on HIV/AIDS and other reproductive-health problems Empirical Financial, incremental, provider perspective (upstream system costs excluded) Top-down 3 per HCT visit
Minh (2012)95 2008 Viet Nam Not clear 6 facility-based and 2 free-standing VCT units A one-on-one pre-test counselling session – including a personal risk assessment and risk-reduction plan – was followed by testing and post-test counselling Empirical Economic and financial, full, provider perspective Top down 32 and 41 per VCT visit to the facility-based and free-standing units, respectively
Global
Marseille (2007)96 2004 a) India
b) Mexico
c) the Russian Federation
d) South Africa
e) Uganda
Not clear Prevention sites per country
a) 17
b) 18
c) 10
d) 14
3) 14
Prevent AIDS: Network for Cost-Effectiveness Analysis examined multiple interventions in varied organizational settings and countries. It has the purpose of providing essential information and analysis for an improved allocation of HIV prevention funds in low and middle income countries Empirical, examined the association between scale and efficiency using regression modelling Financial, economic, provider perspective Bottom up Not available

AIDS: acquired immunodeficiency syndrome; ANC: antenatal care; ART: antiretroviral therapy; CDC: United States Centers for Disease Control and Prevention; ELISA: enzyme-linked immunosorbent assay; eMTCT: elimination of mother-to-child transmission; FP: family planning; HCT: human immunodeficiency virus counselling and testing; HIV: human immunodeficiency virus; IEC: information, education and communication; NGO: nongovernmental organization; OI: opportunistic infections; SRH: sexual and reproductive health; STI: sexually transmitted infection; TB: tuberculosis; US$: United States dollars; VCT: voluntary counselling and testing.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS. For brevity, only the first author of each publication is shown. The publications generally provide much more detail about costings and the assumptions made in evaluating costs than can be neatly summarized here.

b Costs have been adjusted to the dollar values for the year 2011 and then rounded to integer values. They are financial unless indicated otherwise.

c Although the published results of this study do not state when data were collected, the published costs are given as values for the year shown here.

Table 13. Studies on key-population programmes included in the systematic review.

Region and referencea Last year of data collection Country Location No. and types of sites Description of interventions and models Empirical or modelled Costing scope Costing method Mean unit cost(s), US$ (range)b
Africa – eastern and southern
Moses (1991)71 1990c Kenya Urban 1 health clinic A programme for STI/HIV control that used a primary-health-care approach among female SWs. General health services were provided free of charge at the health clinic investigated. Health education and counselling and testing related to STI and HIV were provided as required. Health assessments were provided every 6 months. Condoms were supplied free of charge Empirical (data from a cohort of over 1000 SWs) Financial, provider perspective Bottom-up 123 per female SW, 13–19 per HIV infection averted
Chang (2013)72 2008 Uganda Urban 29 peer health workers in 10 clinics A cluster randomized trial to determine whether peer health workers improved the outcomes of AIDS care. Peer health workers provided clinical and adherence monitoring and psychosocial support to fellow patients, at clinics and during monthly home visits. In a substudy, some peer health workers received mobile phones so that they could send patients’ clinical data to centralized staff Empirical Economic, provider and societal perspectives, costing analysis Combination of top-down and bottom-up 16 (including supervision costs) and 9 (excluding supervision costs) per patient-year in main study, 2 per patient-year in substudy
Asia and Pacific
Guinness (2010)73 2007 Bangladesh National 21 project sites (5 in 1998–1999, 7 in 1999–2000 and 9 in 2000–2001), together covering 82 892 visits to IDUs Study of the Bangladesh CARE-SHAKTI programme for IDUs. This was a harm-reduction programme providing needle and syringe exchange, abscess management, treatment of STIs, education and condom distribution Empirical (primary data) and model Economic, incremental and full, provider perspective Ingredients approach 10 (8–11) per contact
Guinness (2005)75 2002 India National 17 NGOs HIV-prevention interventions run by selected NGOs and targeted at SWs Empirical Economic, full, provider perspective Ingredients approach 23 (12–61) per person reached
Dandona (2005)74 2003 India National 15 HIV-prevention programmes, which together provided services to 33 941 female sex workers in 2002–2003 Programmes to prevent HIV infection among female SWs were run by NGOs in Andhra Pradesh, with the support of the Andhra Pradesh AIDS Control Society Empirical Economic, incremental, provider perspective Combination of top-down and bottom-up 17 (6–34) per person reached, 2 (1–4) per contact
Fung (2007)76 2003 India Urban 2 surveys of commercial SWs A dynamic mathematical model was used, with survey and intervention-specific data from Ahmedabad, to estimate the impact of the Jyoti Sangh project over the 51 months between two surveys of commercial SWs in Ahmedabad. The project was based on outreach, peer education, condom distribution and free STI clinics Empirical (primary data) and model Economic and financial, provider perspective Combination of top-down and bottom-up Financial costs of 102 per SW reached and 70 (40–158) per HIV infection averted – with corresponding economic costs of 248 and 116 (2–9), respectively
Dandona (2008)77 2003 and 2006 India National 14 programmes for HIV prevention among SWs Study to explore possible reasons for changes in the unit costs of the HIV-prevention services that were targeted at SWs between 2003 and 2006 Empirical Economic, provider perspective Bottom-up 13 (6–34) per SW in 2003, 35 (24–64) in 2006
Chandrashekar (2010)79 2006 India National 26 districts (15 in the first year and 11 in the second) covering 38 NGO projects. Services assumed to be integrated. Study covered 124 669 female and male SWs who received STI services via NGO-run projects. Interventions designed to reduce HIV risk through outreach, behaviour-change communications on safe sex, free or socially marketed condoms, needle and syringe exchange (for injecting-drug use) and treatment of STIs, as well as structural interventions and community mobilization Empirical Financial and economic, full, provider perspective Combination of top-down and bottom-up 185 (20–725) per person reached and 149 (41–458) per person receiving STI services – with corresponding values from a sensitivity analysis of 182 (20–687) and 88 (25–458), respectively
Dandona (2010)56 2006 India National HIV-prevention programmes serving 190 599 high-risk individuals over 4 years. Services not assumed to be integrated. Public-funded HIV-prevention intervention focusing on condom promotion among female SWs, men who have sex with men, and truck drivers Empirical (primary data) Economic, provider perspective Combination of top-down and bottom-up 36 per SW reached, 9 per man who has sex with men, 3 per truck driver
Kumar (2009)78 2006 India National 6 out of 21 HIV-prevention programmes were randomly sampled to obtain a representative sample for the state of Andhra Pradesh Study of HIV-prevention programmes run by NGOs for truck drivers in Andhra Pradesh. The target group includes both truck drivers and their assistants who are commonly referred to as “helpers” or “cleaners” Empirical Economic, provider perspective Combination of top-down and bottom-up 3 (2–5) per person reached, 1 (1–2) per contact
Siregar (2011)80 2008 Indonesia Urban 1 hospital clinic, 1 HIV community clinic, 1 STI community clinic and 1 prison clinic (with 568, 28, 784 and 574 clients, respectively) All but the prison clinic offered complete VCT package, including pre- and post-test counselling and HIV testing. Each site was distinct in terms of the characteristics of the clients, HIV-positive cases and setting and the VCT procedures Empirical Financial, provider and societal perspectives Combination of top-down and bottom-up 78, 68, 41 and 24 per HCT client in the hospital and HIV community, STI community and prison clinics, respectively
Eastern Europe and central Asia
Kumaranayake (2004)81 1998 Belarus Urban 2 syringe-exchange points for IDUs A project for the prevention of HIV infection among IDUs in the city of Svetlogorsk was initiated in 1997 by an NGO. This project included the distribution of syringes, condoms and IEC materials related to HIV prevention and harm reduction at two syringe-exchange points. A dynamic mathematical model was used to estimate the cost – per HIV infection averted among both IDUs (n = 565) and non-IDUs – of the project Empirical and model Economic and financial, provider perspective Ingredients approach 70 (financial) and 138 (economic) per person reached
Vickerman (2006)82 2000 Ukraine Urban 3 outreach points for IDUs – 2 were stationary (at the Regional Narcological Clinic and a polyclinic) and the other was mobile Data came from behavioural surveys among IDUs in Odessa, in 1999 (n = 177), 2000 (n = 293) and 2001 (n = 97). A mathematical model was used to estimate the impact of the Odessa IDU Project – in terms of HIV infections averted – and the Project’s cost–effectiveness. The patterns of HIV and STI transmission resulting from syringe sharing and sexual contact between IDUs and their sexual partners were simulated Empirical (primary data) and model Financial and economic, provider perspective Combination of top-down and bottom-up 5 (financial) and 13 (economic) per person reached
Global
Marseille (2007)96 2004 a) India
b) the Russian Federation
c) South Africa
Not Clear Prevention sites per country
a) 15
b) 16
c) 15
Prevent AIDS: Network for Cost-Effectiveness Analysis (PANCEA) examined multiple interventions in varied organizational settings and countries. It has the purpose of providing essential information and analysis for an improved allocation of HIV prevention funds in low and middle income countries. The study includes in total five countries: India, Mexico, the Russian Federation, South Africa, and Uganda Empirical, examined the association between scale and efficiency using regression modelling Financial, economic, provider perspective Bottom up Not available

AIDS: acquired immunodeficiency syndrome; HCT: human immunodeficiency virus counselling and testing; HIV: human immunodeficiency virus; IDU: injecting drug user; IEC: information, education and communication; NGO: nongovernmental organization; STI: sexually transmitted infection; SW: sex worker; US$: United States dollars; VCT: voluntary counselling and testing.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS. For brevity, only the first author of each publication is shown. The publications generally provide much more detail about costings and the assumptions made in evaluating costs than can be neatly summarized here.

b Costs have been adjusted to the dollar values for the year 2011 and then rounded to integer values.

c This year has been assumed. The published results of this study do not state when data were collected.

Table 14. Studies on voluntary medical male circumcision included in the systematic review.

Region and referencea Last year of data collection Country Location No. and types of sites Description of interventions and models Empirical or modelled Costing scope Costing method Mean unit cost(s), US$ (range)b
Africa – eastern and southern
Futures Institute83 and Kioko, personal communication (2010)c 2009 Kenya Nyanza province 30 sites (16 outreach and 14 static): 7 hospitals, 3 district hospitals, 5 subdistrict hospitals, 8 health centres and 7 dispensaries Cost analysis of MMC and impact of a programme of scale-up at both outreach and static sites Empirical Financial, full, provider perspective Bottom-up 40 (36–42) per MMC in outreach sites, 32 (31–47) in static sites
Martin (2007)85 2007 Lesotho National 4 public hospitals Assessment of the cost of providing adult MMC in a resource-constrained setting and evaluate the implications of scaling up MMC – for the future cost–effectiveness of MMC and the health system in general for the period 2008–2020 Empirical and model Financial, provider perspective Bottom-up, ingredients approach 61 per MMC
Binagwaho (2010)84 2008d Rwanda National No information on sites available Infant circumcision was integrated into existing neonatal and vaccination services. In a cost–effectiveness model, three hypothetical male cohorts for the provision of MMC were considered: adults, adolescents and neonates Model (secondary data) Financial, full, government health-care payer perspective Bottom-up Among adults and adolescents, 62 and 62 per MMC, 5171 and 4108 per HIV infection averted and 641 and 349 per life year saved, respectively; among neonates, 16 per MMC
USAID (2010)86 2009 South Africa National 20 health facilities, including 8 public-sector district hospitals, 6 health centres, 3 private general practitioners and 1 NGO clinic Cost analysis of the impact of scaling up MMC Empirical Financial, full, provider perspective Bottom-up 70 (47–81) per MMC with no complications, 71 (46–89) per MMC with complications
USAID (2010)87 2009 Uganda National 27 health facilities, including public hospitals, health centres, private for-profit units and NGO hospitals Cost–effectiveness model assessing the potential impact and costs of scaling up of MMC services among three cohorts: adolescent males before sexual debut, all adults aged 15–29 years, and high-risk groups Empirical (primary data) Financial, full, provider perspective Bottom-up 19 (9–35)·per MMC among adolescent males and 22 (12–36) among adults aged 15–29 years; among high-risk groups, 2383 per MMC by medical officer, 1209 per MMC by surgeon and 1444·per HIV infection averted
Futures Institute83 and Chiwevu, personal communication (2010)e 2009 Zambia National 17 health facilities, including 8 provincial hospitals, 8 district hospitals and a private facility Cost analysis of MMC and impact of scaling up MMC programme Empirical Financial, full, provider perspective Bottom-up 74 (50–98) per MMC. Net savings of 5746 (4637–6855) per HIV infection averted
USAID (2010)88 2009 Zimbabwe Unclear 1 stand-alone site for MMC and 1 public site within a family planning clinic Cost analysis of MMC and impact of scaling up MMC programme in static and outreach sites Empirical Financial, full, provider perspective Bottom-up 60 per MMC in static sites and 72 in outreach sites

HIV, human immunodeficiency virus; MMC, medical male circumcision; NGO, nongovernmental organization; US$, United States dollars; USAID, United States Agency for International Development.

a The region shown is one defined and commonly used by the Joint United Nations Programme on HIV/AIDS.

b Costs have been adjusted to the dollar values for the year 2011 and then rounded to integer values.

c Some details of the study were provided by UM Kioko (Centre for Economic and Social Research, University of Nairobi, Kenya).

d Although the published results of this study do not state when data were collected, the published costs are given as values for the year shown here.

e Some details of the study were provided by C Chiwevu (Johannesburg, South Africa), who is an independent consultant.

Table 15. Studies on the elimination of mother-to-child transmission included in the systematic review.

Region and referencea Last year of data collection Country Location No. and types of sites Description of interventions and models Empirical or modelled Costing scope Costing method Mean unit cost(s), US$ (range)b
Africa – eastern and southern
Orlando (2010)89 2008 Malawi Urban 2 health centres Assessment of the cost–effectiveness of a HAART-based intervention targeted at pregnant women, compared with a no-intervention scenario. The intervention included VCT and adopted a holistic approach combining HAART – irrespective of the woman’s immunological status, from week 25 of the pregnancy – with the treatment of malnutrition, TB, malaria and STIs. HAART was administered during breastfeeding until 6 months after delivery (if the women chose to breastfeed after being counselled) Empirical Economic, private and public provider perspective Ingredients approach 395 per pregnant patient, 72 per woman on programme, 1077 per HIV infection averted
McMennamin (2007)94 2007 Rwanda Rural and periurban 6 health centres (5 rural and 1 periurban) A costing study to inform performance-based financing and contracting for HIV services in Rwanda, including unit costs for eMTCT, VCT and OI services in 2005 Empirical Financial, provider perspective Micro-costing, bottom-up 7 per consultation
Wilkinson (1998)97 1997 South Africa Rural No data available A mathematical model was used to compare a no-intervention scenario with three interventions for eMTCT: AZT delivered within the current infrastructure (Scenario A), AZT delivered via an enhanced infrastructure (Scenario B), and short-course AZT plus 3TC delivered through an enhanced infrastructure (Scenario C) Model (primary data) Financial, incremental Micro-costing, top-down For Scenarios A, B and C, costs were 7817, 7528 and 3355 per paediatric HIV infection prevented and 276–479, 267–462 and 118–206 per life year gained, respectively
Desmond (2004)90 2002 South Africa Urban ANC delivered by 4 hospitals or hospital-based clinics Part of a larger evaluation of the pilot eMTCT programme in South Africa commissioned by the Health Systems Trust on behalf of the Department of Health. The specific objectives of the research were to undertake a costing exercise of the national eMTCT protocol in four eMTCT pilot sites, assess sources of funding for the eMTCT intervention and provide a range of costing data for informing the funding requirements of a national roll-out of the eMTCT programme and for policy, planning and management purposes Empirical Economic and financial, provider perspective Bottom-up 457 (337–709) (financial) and 821 (494–1128) (economic) per mother–neonate pair followed up, 244 (68–566) (financial) and 314 (79–618) (economic) per mother–neonate pair receiving NVP, 52 (18–84) (financial) and 90 (22–204) (economic) per person post-test counselled, 70 (18–119) (financial) and102 (25–217) (economic) per person pre-test counselled, 49 (20–79) (financial) and 104 (33–223) (economic) per person tested for HIV
Robberstad (2010)98 2007 United Republic of Tanzania Rural 28 sites for reproductive and child health services eMTCT of HIV in the Haydom area was organized through four different but interlinked programmes: an eMTCT programme, a programme of care and treatment, a programme of maternity-ward interventions and a programme for community home-based care. The prevention programme, which was characterized by extensive outreach designed to prevent and provide testing for HIV infection, was organized through general VCT services in 74 villages and through 28 sites for reproductive and child health services Empirical Financial Top-down 12 per woman reached
Stringer (2003)99 2001 Zambia Urban 9 public delivery centres, at which VCT had been integrated into existing antenatal services Provision of VCT and prophylactic ART for pregnant women Empirical Financial, full Top-down 12 per patient counselled, 16 per patient tested, 69 per seropositive woman identified, 1067 per HIV infection averted
Bratt (2011)37 2009 Zambia Urban and rural 12 facilities supported by the Zambian Prevention, Care and Treatment Partnership. From these 3 hospitals and 5 health centres provided eMTCT services.
Services were integrated
Initiating, improving and scaling up eMTCT, HCT and clinical-care services, for people living with HIV, during ANC and PNC in urban and rural settings Empirical (resource use estimated from primary data) Economic, full, provider perspective Combined top-down and bottom-up eMTCT cost 57 (48–75) per antenatal visit, 27 (19–38) per postnatal visit, 35 (19–51) per urban eMTCT visit and 54 (31–75) per rural eMTCT visit
Asia and Pacific
Dandona (2008)91 2003 and 2006 India National 16 public-sector hospitals, some of which are attached to a medical college Provision of HCT for pregnant women and provision of ART at the time of delivery if the women are HIV-positive Empirical (resource use estimated) Economic and financial, incremental Gross costing, top-down 2 (2–5) per client post-test counselled, 258 (109–4512) per mother–neonate pair receiving NVP
Global
Marseille (2007)96 2004 India Unclear 15 prevention sites Prevent AIDS: Network for Cost-Effectiveness Analysis (PANCEA) examined multiple interventions in varied organizational settings and countries. It has the purpose of providing essential information and analysis for an improved allocation of HIV prevention funds in low and middle income countries. The study includes in total five countries: India, Mexico, the Russian Federation, South Africa, and Uganda Empirical, examined the association between scale and efficiency using regression modelling Financial, economic, provider perspective Bottom up Not available
Nakakeeto (2009)100 2007c Burkina Faso, Cameroon, Côte d’Ivoire, Malawi, Rwanda, United Republic of Tanzania, Zambia National No integration Promotion of FP to people living with HIV, HCT for pregnant women in ANC and provision of ART and cotrimoxazole prophylaxis to HIV-infected women and cotrimoxazole prophylaxis to HIV-exposed infants Model (secondary data) Financial Micro-costing, bottom-up 1387 (798–7360) per HIV infection averted

3TC: lamovudine; ANC: antenatal care; ART: antiretroviral therapy; AZT: zidovudine; eMTCT: elimination of mother-to-child transmission; FP: family planning; HAART: highly-active antiretroviral therapy; HCT: human immunodeficiency virus counselling and testing; HIV: human immunodeficiency virus; NVP: nevirapine; OI: opportunistic infections; PNC: postnatal care; STIs: sexually transmitted infections; TB: tuberculosis; US$: United States dollars; VCT: voluntary counselling and testing.

a The regions shown are those defined and commonly used by the Joint United Nations Programme on HIV/AIDS. For brevity, only the first author of each publication is shown. The publications generally provide much more detail about costings and the assumptions made in evaluating costs than can be neatly summarized here.

b Costs have been adjusted to the dollar values for the year 2011 and then rounded to integer values.

c Although the published results of this study do not state when data were collected, the published costs are given as values for the year shown here.

Economies of scale

The key findings from 40 studies found exploring costs and economies of scale are summarized in Appendix A. Only nine of these studies had sufficiently large samples to apply econometric methods to explore any associations between scale and costs.23,69,74,75,7779,93,96 Most of these studies were focused on HIV prevention among key populations. None covered condom distribution, male circumcision or interventions that were targeted at men who have sex with men. Scale was often found to explain statistically significant proportions of the variability seen in unit costs – including 48%, 42%, 28–83%, 25–88% and 45–96% of such variability in an ART programme,23 a programme for the elimination of mother-to-child transmission of HIV infection,96 HIV counselling and testing,69,96 and programmes targeting sex workers69,74,75,77,79,96 and people who inject drugs,96 respectively.

The only evidence of a diseconomy of scale96 that we found in the results of econometric studies was the observation that a quadratic function provided a fairly good fit to the cost data observed in one such investigaton.91

In several descriptive studies, unit costs for HIV services appeared to be influenced by the link between scale and the achievement of optimal staff workloads.23,37,55,64 As a programme ages, unit costs may either increase79 or – if the programme scales up over time – decrease.20,27,73 Any cost reductions that occur during scale-up may result from “learning by doing” and task shifting.20,32,39,43

Economies of scope

We reviewed 23 studies that reported both unit costs and economies of scope, including 12 studies20,24,31,33,46,52,63,64,69,88,91,95 that were not included in the earlier review by Sweeney et al. (2012).9 Most of the 23 studies related to HIV counselling and testing (n = 18) or ART (n = 3) but we also analysed single studies on three other types of programme: behaviour-change communications, male circumcision and the elimination of mother-to-child transmission (Appendix A).

Although the integration of voluntary HIV counselling and testing with other health services was found to improve quality, increase the utilization of services and reduce the cost per visit in some programmes,57,61,70 it was found to increase costs in other programmes.20,95 Compared with the costs of stand-alone services, the integration of HIV counselling and testing with other health services has been reported to reduce unit costs – of the counselling and testing – by between 17% and 79%.9,57,59,61,63,64,67,70,95 In terms of the unit costs per HIV infection identified, provider-initiated voluntary testing and counselling was found to be less than half as expensive as client-initiated counselling and testing.64 When counselling and testing were integrated with other health services, a strong and functioning referral system was found to be important for creating demand.9,24,25,29,31,33,35,45,63,67,69,70

Other pathways to improve efficiency

Our systematic review revealed evidence of many other determinants of costs and efficiency besides economies of scale and scope (Appendix A). Although task shifting was observed to reduce costs, there were concerns that it might also reduce service quality.30 In India, costs incurred above the level of service delivery have been reported to account for 35 to 46% of the unit costs of HIV prevention.43 Loss to follow-up may be a key source of inefficiency in ART programmes – resulting in a 15 to 55% increase in the unit costs per patient treated.29,31,33

We found limited evidence of possible gains from targeting specific groups of patients and clients4,58,60,63,64,67 and little examination of the trade-off between the costs of targeting and efficiency gains. We also found no studies in which the cost efficiency of providing more intense services to a particular group was compared with that of providing a minimal service to a larger population group.

Discussion

There is a growing evidence base on the costs of delivering ART, HIV counselling and testing, interventions for condom distribution and the prevention of mother-to-child transmission of HIV, voluntary medical male circumcision and key-population programmes in low- and middle-income countries. While some of the differences observed in the unit costs are likely to be explained by environmental factors, the wide variation indicates there is general room for improvement in the technical efficiency of HIV services.

In our systematic review, evidence of economies of scale in all of the studies enabled a robust examination of the relationship between scale and costs. HIV services should therefore be focused on sites with sufficient demand for such services. In the “free market”, economies of scale generally lead to mergers that create large-scale providers and large production units. However, where populations are dispersed, a balance needs to be sought between provider costs and the costs incurred by clients as they access care. Several of the studies that we reviewed demonstrated the high health care costs for patients.3638,40,58 The burden of these “client-side” costs may need to be shifted to service providers – through the provision of more accessible services or, possibly, by reimbursing each patient’s travel costs. Such changes may limit the extent to which economies of scale are realized. Although the high costs to patients of accessing care might be reduced by providing mobile or home-based services, there is little evidence to show that the implementation of such services reduces provider costs. Some degree of trade-off may have to be made between client and provider costs.3537

Unit costs may often be reduced by increasing staff workloads.28,31,32,36,39,47,64 In optimizing staff workloads, supply of staff has to be matched with the demand for services. On the supply side, the extent to which staffing levels are fixed is often either an artefact of human-resource planning – in which staffing complements are defined using norms, irrespective of the workload or demand per site – or a reflection of minimum clinical requirements. In many settings, the creation of demand – where there is a need – may be the only way to optimize workloads. Demand may be increased by identifying new clients, improving adherence and reducing loss to follow-up.59,99 Within staffing norms, there may still be flexibility within staffing allocations at site level. Site or programme managers must be provided with the data and means to allocate staff in a responsive manner. Task shifting may reduce both provider costs – by lowering the cost of salaries and increasing flexibility around any minimum staffing requirements101 – and client costs – by allowing services to be delivered from sites that are relatively close to the clients and run by lower-level staff.102 In the future, new technologies, such as the non-surgical PrePex method of circumcision, may further reduce the need for high-level clinical staff.30,32,66,87 However, the current evidence of the impact on task shifting on costs remains inconsistent93 and there remain concerns that task shifting may lead to poor morale among lower-paid staff and lower service quality.85,102

Our current findings on economies of scale generally support the assumptions made in the UNAIDS Strategic Investment Framework on the existence of economies of scale with programmes of HIV counselling and testing and HIV prevention for key populations. However, economies of scale at the programme level tend to differ from those at site level. The evidence presented here refers to the relationship between costs and site scale. Although costs incurred above the service level are likely to be fixed, economies of scale derived from site-level costings may often still underestimate the corresponding programmatic economies of scale.24,37,43,56 In some cases, programmes may suffer from diseconomies of scale as they increase the number of service providers to reach groups that are particularly hard to reach. We found almost no evidence of diseconomies of scale56,61,81 but the relevant evidence base was relatively small. It should not be assumed that diseconomies of scale do not exist.

While there is a broad evidence base on the cost–effectiveness of some integrated HIV services,9 there is considerably less information available on the corresponding economies of scope.9,63,67,70,95 The economies of scope that have been reported may only represent the indirect effects of economies of scale – that is, integration may simply have brought HIV services to new clients rather than improved efficiency through the joint provision of services.70

Most of the other factors that have been found to influence unit costs are also potentially within the control of managers of HIV programmes. Reductions in commodity prices, especially those for first- and second-line antiretroviral drugs, have the potential to yield substantial cost savings. Such reductions may be achieved via revised national tenders, joint procurement, improved forecasting, and process efficiency and transparency.33,45,46,48 Cost savings achieved by reducing the price of second-line therapy will continue to be critical in low- and lower-middle-income countries, where patients are particularly likely to switch to second-line regimens over time.

Few of the studies that we reviewed incorporated any analysis of the quality of service provision. However, where quality and costs were jointly examined, cost reduction often led to reduced quality.26,29,33,35,37,40,46,92 In a large review of 15 ART programmes in Africa, Asia and Latin America, it was found that increases in the scale of a programme led to increases in the rates of loss to follow-up.103 Compared with small programmes, large-scale programmes were less likely to follow up patients actively.103 Unfortunately, little is known about the potential “cost–quality trade-off” of the alternative service models that may be adopted to reduce unit costs, such as reducing the number of visits required for ART monitoring. Support for managers at the site and district level – for example, to allow costs to be monitored and “blueprint” approaches to be avoided – may be key to ensuring that efforts to improve efficiency do not damage staff morale or service quality.30,57,58,64 When setting national and international cost benchmarks, attention must also be taken not to create perverse incentives by emphasizing measurable costs rather than the more intangible aspects of service quality.

We were unable to find much published information on the unit costs of several of the key interventions included in the UNAIDS Strategic Investment Framework. Most notably, there is a dearth of data on the costs of ART for key populations, condom distribution in general, HIV counselling and testing beyond Africa, key population interventions outside India, and large-scale programmes for the prevention of mother-to-child transmission of HIV and male circumcision. Most of the relevant studies in which economies of scale or scope were investigated had small samples. It remains unclear whether economies of scale or scope vary by provider type or other site or service characteristics. Studies that include the full range of costs and uncertainty analysis of cost estimates and have samples large enough to show all cost variation in detail remain rare. There is also a distinct lack of experimental studies that have been designed to detect the sources of inefficiency. Despite these limitations, there are signs of recent improvements in the costing of HIV services. Most of our main findings were derived from studies conducted over the last five years. There is also some evidence that cost reductions are already being achieved as HIV programmes mature93 and, in the future, there may be further scope for efficiency gains as new technologies and service models are developed.

Large-scale costing studies that cover the full range of HIV services are required. Empirical costing studies of activities above the service level are also needed to provide insights into approaches for optimizing programme costs. In the future, experimental studies – especially on actions to enhance planning and management capacity, the utilization of human resources, financial and information systems, demand generation and service integration – could allow efficiency to be improved. If essential HIV services are to be made cheaper and sustainable, the policy-makers involved with HIV will probably have to engage with those involved in improving the efficiency and capacity of general systems for health care and community support.

In conclusion, the general efficiency of HIV services must be improved if core interventions are to be successfully scaled up in environments where resources are scarce. At site level, economies of scale can often be made. The integration of HIV services with other health services may also reduce costs. Further studies are required to determine the best ways of improving the efficiency of HIV services at site level and the likely impact of such improvements on the national costs of HIV services.

Funding:

This work was supported by UNAIDS.

Competing interests:

None declared.

References

  • 1.The Millennium Development Goals report 2012. New York (NY): United Nations; 2012. [Google Scholar]
  • 2.2011 United Nations General Assembly Political Declaration on HIV/AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2011. [Google Scholar]
  • 3.Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359:1635-43 10.1016/S0140-6736(02)08595-1 [DOI] [PubMed] [Google Scholar]
  • 4.Galárraga O, Colchero MA, Wamai RG, Bertozzi SM. HIV prevention cost-effectiveness: a systematic review. BMC Public Health. 2009;9Suppl 1;S5 10.1186/1471-2458-9-S1-S5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Financing global health 2012: the end of the golden age? Seattle (WA): Institute for Health Metrics and Evaluation; 2012. [Google Scholar]
  • 6.Together we will end AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2012. [Google Scholar]
  • 7.Galárraga O, Wirtz VJ, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, Viisainen K,et al. Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics. 2011;29:579-99 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Johns B, Torres TT; WHO-CHOICE. Costs of scaling up health interventions: a systematic review. Health Policy Plan. 2005;20:1-13 10.1093/heapol/czi001 [DOI] [PubMed] [Google Scholar]
  • 9.Sweeney S, Obure CD, Maier CB, Greener R, Dehne K, Vassall A. Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience. Sex Transm Infect. 2012;88:85-99 10.1136/sextrans-2011-050199 [DOI] [PubMed] [Google Scholar]
  • 10.Uyei J, Coetzee D, Macinko J, Guttmacher S. Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. Lancet. Infect Dis. 2011;11:855-67 10.1016/S1473-3099(11)70145-1 [DOI] [PubMed] [Google Scholar]
  • 11.Vassall A, Compernolle P. Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners. Health Policy. 2006;79:1-15 10.1016/j.healthpol.2005.11.005 [DOI] [PubMed] [Google Scholar]
  • 12.Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy Plan. 2003;18:4-17 10.1093/heapol/18.1.4 [DOI] [PubMed] [Google Scholar]
  • 13.Santa-Ana-Tellez Y, DeMaria LM, Galárraga O. Costs of interventions for AIDS orphans and vulnerable children. Trop Med Int Health. 2011;16:1417-26 10.1111/j.1365-3156.2011.02856.x [DOI] [PubMed] [Google Scholar]
  • 14.Zeng W, Shepard DS, Chilingerian J, Avila-Figueroa C. How much can we gain from improved efficiency? An examination of performance of national HIV/AIDS programs and its determinants in low- and middle-income countries. BMC Health Serv Res. 2012;12:74 10.1186/1472-6963-12-74 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E,et al. ; Investment Framework Study Group. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377:2031-41 10.1016/S0140-6736(11)60702-2 [DOI] [PubMed] [Google Scholar]
  • 16.Moher D, Liberati A, Tetzlaff J, Altman DG;PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Shepperd S, Lewin S, Straus S, Clarke M, Eccles MP, Fitzpatrick R,et al. Can we systematically review studies that evaluate complex interventions? PLoS Med. 2009;6:e1000086 10.1371/journal.pmed.1000086 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.How we classify countries [Internet]. Washington (DC): World Bank; 2012. Available from: http://data.worldbank.org/about/country-classifications [cited 2013 Oct 19].
  • 19.Drummond MF, Jefferson TO; The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-83 10.1136/bmj.313.7052.275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV,et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011;25:1753-60 10.1097/QAD.0b013e3283463eec [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bikilla AD, Jerene D, Robberstad B, Lindtjorn B. Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. Cost Eff Resour Alloc . 2009;7:6 10.1186/1478-7547-7-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kombe G, Galaty D, Gadhia R, Decker C. The human and financial resource requirements for scaling up HIV/AIDS services in Ethiopia. Bethesda (MD): Abt Associates; 2005. Available from: http://www.abtassociates.com/reports/AB_PNADC109.pdf [cited 2013 Oct 19].
  • 23.Marseille EA, Kevany S, Ahmed I, Feleke G, Graham B, Heller T,et al. Case management to improve adherence for HIV-infected patients receiving antiretroviral therapy in Ethiopia: a micro-costing study. Cost Eff Resour Alloc. 2011;9:18 10.1186/1478-7547-9-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cleary S, Tshehlo R, Jouquet G, Makakole L. Ensuring access to free HIV/AIDS care and treatment in Lesotho. Cape Town: University of Cape Town; 2007. Available from: http://196.202.240.21/mcaweb/documents/Health/HEALTH%20Decentralization%20of%20ART.pdf [cited 2013 Oct 19].
  • 25.Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa – a primary data analysis. Cost Eff Resour Alloc. 2006;4:20 10.1186/1478-7547-4-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Deghaye N, Pawinski RA, Desmond C. Financial and economic costs of scaling up the provision of HAART to HIV-infected health care workers in KwaZulu-Natal. S Afr Med J. 2006;96:140-3 [PubMed] [Google Scholar]
  • 27.Harling G, Bekker LG, Wood R. Cost of a dedicated ART clinic. S Afr Med J. 2007;97:593-6 [PubMed] [Google Scholar]
  • 28.Harling G, Wood R. The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr. 2007;45:348-54 [DOI] [PubMed] [Google Scholar]
  • 29.Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008;13:1005-15 10.1111/j.1365-3156.2008.02114.x [DOI] [PubMed] [Google Scholar]
  • 30.Vella V, Govender T, Dlamini S, Taylor M, Moodley I, David V, et al. Evaluation of antiretroviral therapy against HIV/Aids in KwaZulu-Natal, South Africa. Pietermaritzburg: KwaZulu-Natal Department of Health; 2008. Available from: http://www.kznhealth.gov.za/italian/arv.pdf [cited 2013 Oct 19].
  • 31.Kevany S, Meintjes G, Rebe K, Maartens G, Cleary S. Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G.F. Jooste Hospital). S Afr Med J. 2009;99:320-5 [PubMed] [Google Scholar]
  • 32.Martinson N, Mohapi L, Bakos D, Gray GE, McIntyre JA, Holmes CB. Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009;50:327-30 10.1097/QAI.0b013e3181958546 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24:915-9 10.1097/QAD.0b013e3283360976 [DOI] [PubMed] [Google Scholar]
  • 34.Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, Sanne I,et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011;8:e1001055 10.1371/journal.pmed.1001055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Babigumira JB, Sethi AK, Smyth KA, Singer ME. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics 2009;27:963-73 10.2165/11318230-000000000-00000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Jaffar S, Amuron B, Foster S, Birungi J, Levin J, Namara G,et al. ; Jinja Trial Team. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet. 2009;374:2080-9 10.1016/S0140-6736(09)61674-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bratt JH, Torpey K, Kabaso M, Gondwe Y. Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities. Trop Med Int. Health 2011;16:110-8 10.1111/j.1365-3156.2010.02640.x [DOI] [PubMed] [Google Scholar]
  • 38.Hounton SH, Akonde A, Zannou DM, Bashi J, Meda N, Newlands D. Costing universal access of highly active antiretroviral therapy in Benin. AIDS Care. 2008;20:582-7 10.1080/09540120701868303 [DOI] [PubMed] [Google Scholar]
  • 39.Renaud A, Basenya O, de Borman N, Greindl I, Meyer-Rath G. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009;21:1388-94 10.1080/09540120902884042 [DOI] [PubMed] [Google Scholar]
  • 40.Kombe G, Galaty D, Nwagbara C. Scaling-up antiretroviral treatment in the public sector in Nigeria: a comprehensive analysis of resource requirements [Internet]. Bethesda (MD): Abt Associates; 2004. Available from: http://www.healthsystems2020.org/content/resource/detail/1489/ [cited 2013 Oct 19].
  • 41.Partners for Health Reformplus. Nigeria: rapid assessment of HIV/AIDS care in the public and private sectors [Internet]. Bethesda (MD): Abt Associates; 2004. Available from: http://www.healthsystems2020.org/content/resource/detail/1619/ [cited 2013 Oct 19].
  • 42.Aliyu HB, Chuku NN, Kola-Jebutu A, Abubakar Z, Torpey K, Chabikuli ON. What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria? J Acquir Immune Defic Syndr. 2012;61:221-5 10.1097/QAI.0b013e3182683b04 [DOI] [PubMed] [Google Scholar]
  • 43.Gupta I, Trivedi M, Kandamuthan S. Recurrent costs of India’s free ART program. In: Haacker M, Claeson M, editors. HIV and AIDS in South Asia: an economic development risk. Washington: World Bank; 2009. pp. 191-237. [Google Scholar]
  • 44.John KR, Rajagopalan N, Madhuri KV. Brief communication: economic comparison of opportunistic infection management with antiretroviral treatment in people living with HIV/AIDS presenting at an NGO clinic in Bangalore, India. MedGenMed. 2006;8:24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kitajima T, Kobayashi Y, Chaipah W, Sato H, Chadbunchachai W, Thuennadee R. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand. AIDS. 2003;17:2375-81 10.1097/00002030-200311070-00013 [DOI] [PubMed] [Google Scholar]
  • 46.Koenig SP, Riviere C, Leger P, Severe P, Atwood S, Fitzgerald DW,et al. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc. 2008;6:3 10.1186/1478-7547-6-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Marques HH, Couttolenc BF, Latorre MdoR, Aquino MZ, Aveiro MI, Pluciennik AM. Costs of care provided in a university hospital for children exposed to or infected with the HIV/AIDS. Cad Saude Publica. 2007;23Suppl 3;S402-13 10.1590/S0102-311X2007001500008 [DOI] [PubMed] [Google Scholar]
  • 48.Aracena-Genao B, Navarro JO, Lamadrid-Figueroa H, Forsythe S, Trejo-Valdivia B. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico. AIDS. 2008;22Suppl 1;S141-8 10.1097/01.aids.0000327635.74919.fd [DOI] [PubMed] [Google Scholar]
  • 49.Bautista SA, Dmytraczenko T, Kombe G, Bertozzi SM. Costing of HIV/AIDS treatment in Mexico. Bethesda (MD): Abt Associates; 2003. Available from: www.healthsystems2020.org/files/1574_file_Tech020_fin.pdf [cited 2013 Oct 19].
  • 50.Contreras-Hernandez I, Becker D, Chancellor J, Kühne F, Mould-Quevedo J, Vega G,et al. Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico. Value Health. 2010;13:903-14 10.1111/j.1524-4733.2010.00798.x [DOI] [PubMed] [Google Scholar]
  • 51.Loubiere S, el Filal KM, Sodqi M, Loundou A, Luchini S, Cleary S,et al. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience. Antivir Ther. 2008;13:241-51 [PubMed] [Google Scholar]
  • 52.Hsu J, Zinsou C, Parkhurst J, N’Dour M, Foyet L, Mueller DH. Comparative costs and cost-effectiveness of behavioural interventions as part of HIV prevention strategies. Health Policy Plan. 2013;28:20-9 10.1093/heapol/czs021 [DOI] [PubMed] [Google Scholar]
  • 53.Söderlund N, Lavis J, Broomberg J, Mills A. The costs of HIV prevention strategies in developing countries. Bull World Health Organ. 1993;71:595-604 [PMC free article] [PubMed] [Google Scholar]
  • 54.Terris-Prestholt F, Kumaranayake L, Foster S, Kamali A, Kinsman J, Basajja V,et al. The role of community acceptance over time for costs of HIV and STI prevention interventions: analysis of the Masaka Intervention Trial, Uganda, 1996–1999. Sex Transm Dis. 2006;33Suppl;S111-6 10.1097/01.olq.0000175389.10289.ba [DOI] [PubMed] [Google Scholar]
  • 55.Terris-Prestholt F, Kumaranayake L, Obasi AI, Cleophas-Mazige B, Makokha M, Todd J,et al. From trial intervention to scale-up: costs of an adolescent sexual health program in Mwanza, Tanzania. Sex Transm Dis. 2006;33Suppl;S133-9 10.1097/01.olq.0000200606.98181.42 [DOI] [PubMed] [Google Scholar]
  • 56.Dandona L, Kumar SG, Kumar GA, Dandona R. Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India. BMC Health Serv Res. 2010;10:117 10.1186/1472-6963-10-117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Twahir A, Maggwa BN, Askew I. Integration of STI and HIV/AIDS services with MCH-FP services: a case study of the Mkomani Clinic Society in Mombasa, Kenya. Washington (DC): Population Council; 1996. Available from: http://www.popcouncil.org/pdfs/frontiers/fphivintegrat/Mombassa96.pdf [cited 2013 Oct 19].
  • 58.Sweat M, Gregorich S, Sangiwa G, Furlonge C, Balmer D, Kamenga C,et al. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet. 2000;356:113-21 10.1016/S0140-6736(00)02447-8 [DOI] [PubMed] [Google Scholar]
  • 59.Forsythe S, Arthur G, Ngatia G, Mutemi R, Odhiambo J, Gilks C. Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. Health Policy Plan. 2002;17:187-95 10.1093/heapol/17.2.187 [DOI] [PubMed] [Google Scholar]
  • 60.John FN, Farquhar C, Kiarie JN, Kabura MN, John-Stewart GC. Cost effectiveness of couple counselling to enhance infant HIV-1 prevention. Int J STD AIDS. 2008;19:406-9 10.1258/ijsa.2008.007234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Liambila W, Askew I, Ayisi R, Gathitu M, Mwangi J, Homan R, et al. Feasibility, acceptability, effect and cost of integrating counseling and testing for HIV within family planning services in Kenya. Washington (DC): Population Council; 2008. Available from: http://www.popcouncil.org/pdfs/frontiers/FR_FinalReports/Kenya_CT_FP.pdf [cited 2013 Oct 19].
  • 62.Negin J, Wariero J, Mutuo P, Jan S, Pronyk P. Feasibility, acceptability and cost of home-based HIV testing in rural Kenya. Trop Med Int Health. 2009;14:849-55 10.1111/j.1365-3156.2009.02304.x [DOI] [PubMed] [Google Scholar]
  • 63.Grabbe KL, Menzies N, Taegtmeyer M, Emukule G, Angala P, Mwega I,et al. Increasing access to HIV counseling and testing through mobile services in Kenya: strategies, utilization, and cost-effectiveness. J Acquir Immune Defic Syndr. 2010;54:317-23 10.1097/QAI.0b013e3181ced126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Obure CD, Vassall A, Michaels C, Terris-Prestholt F, Mayhew S, Stackpool-Moore L,et al. ; Integra Research Team. Optimising the cost and delivery of HIV counselling and testing services in Kenya and Swaziland. Sex Transm Infect. 2012;88:498-503 10.1136/sextrans-2012-050544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.McConnel CE, Stanley N, du Plessis JA, Pitter CS, Abdulla F, Coovadia HM,et al. The cost of a rapid-test VCT clinic in South Africa. S Afr Med J. 2005;95:968-71 [PubMed] [Google Scholar]
  • 66.Hausler HP, Sinanovic E, Kumaranayake L, Naidoo P, Schoeman H, Karpakis B,et al. Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ. 2006;84:528-36 10.2471/BLT.04.018606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Menzies N, Abang B, Wanyenze R, Nuwaha F, Mugisha B, Coutinho A,et al. The costs and effectiveness of four HIV counseling and testing strategies in Uganda. AIDS. 2009;23:395-401 10.1097/QAD.0b013e328321e40b [DOI] [PubMed] [Google Scholar]
  • 68.Tumwesigye E, Wana G, Kasasa S, Muganzi E, Nuwaha F. High uptake of home-based, district-wide, HIV counseling and testing in Uganda. AIDS Patient Care STDS. 2010;24:735-41 10.1089/apc.2010.0096 [DOI] [PubMed] [Google Scholar]
  • 69.Dandona L, Sisodia P, Ramesh YK, Kumar SG, Kumar AA, Rao MC,et al. Cost and efficiency of HIV voluntary counselling and testing centres in Andhra Pradesh, India. Natl Med J India. 2005;18:26-31 [PubMed] [Google Scholar]
  • 70.Das R, Biswas K, Panda P, Khan ME, Homan R. Strengthening financial sustainability through integration of voluntary counseling and testing services with other reproductive health services. Washington (DC): Population Council; 2007. Available from: http://www.popcouncil.org/pdfs/frontiers/FR_FinalReports/India_CINI.pdf [cited 2013 Oct 19].
  • 71.Moses S, Plummer FA, Ngugi EN, Nagelkerke NJ, Anzala AO, Ndinya-Achola JO. Controlling HIV in Africa: effectiveness and cost of an intervention in a high-frequency STD transmitter core group. AIDS. 1991;5:407-11 10.1097/00002030-199104000-00008 [DOI] [PubMed] [Google Scholar]
  • 72.Chang LW, Kagaayi J, Nakigozi G, Serwada D, Quinn TC, Gray RH,et al. Cost analyses of peer health worker and mHealth support interventions for improving AIDS care in Rakai, Uganda. AIDS Care. 2013;25:652-6 10.1080/09540121.2012.722600 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Guinness L, Vickerman P, Quayyum Z, Foss A, Watts C, Rodericks A,et al. The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. Addiction. 2010;105:319-28 10.1111/j.1360-0443.2009.02755.x [DOI] [PubMed] [Google Scholar]
  • 74.Dandona L, Sisodia P, Kumar SG, Ramesh YK, Kumar AA, Rao MC,et al. HIV prevention programmes for female sex workers in Andhra Pradesh, India: outputs, cost and efficiency. BMC Public Health. 2005;5:98 10.1186/1471-2458-5-98 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Guinness L, Kumaranayake L, Rajaraman B, Sankaranarayanan G, Vannela G, Raghupathi P,et al. Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ. 2005;83:747-55 [PMC free article] [PubMed] [Google Scholar]
  • 76.Fung IC, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J,et al. Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health. 2007;7:195 10.1186/1471-2458-7-195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Dandona L, Kumar SP, Ramesh Y, Rao MC, Kumar AA, Marseille E,et al. Changing cost of HIV interventions in the context of scaling-up in India. AIDS. 2008;22Suppl 1;S43-9 10.1097/01.aids.0000327622.24232.aa [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Kumar SG, Dandona R, Schneider JA, Ramesh YK, Dandona L. Outputs and cost of HIV prevention programmes for truck drivers in Andhra Pradesh, India. BMC Health Serv Res. 2009;9:82 10.1186/1472-6963-9-82 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Chandrashekar S, Guinness L, Kumaranayake L, Reddy B, Govindraj Y, Vickerman P,et al. The effects of scale on the costs of targeted HIV prevention interventions among female and male sex workers, men who have sex with men and transgenders in India. Sex Transm Infect. 2010;86Suppl 1;i89-94 10.1136/sti.2009.038547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Siregar AY, Komarudin D, Wisaksana R, van Crevel R, Baltussen R. Costs and outcomes of VCT delivery models in the context of scaling up services in Indonesia. Trop Med Int Health. 2011;16:193-9 10.1111/j.1365-3156.2010.02675.x [DOI] [PubMed] [Google Scholar]
  • 81.Kumaranayake L, Vickerman P, Walker D, Samoshkin S, Romantzov V, Emelyanova Z,et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction. 2004;99:1565-76 10.1111/j.1360-0443.2004.00899.x [DOI] [PubMed] [Google Scholar]
  • 82.Vickerman P, Kumaranayake L, Balakireva O, Guinness L, Artyukh O, Semikop T, et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis. 2006;33Suppl;S89-102 10.1097/01.olq.0000221335.80508.fa [DOI] [PubMed] [Google Scholar]
  • 83.Unit cost repository [Internet]. Glastonbury: Futures Institute; 2010. Available from: http://policytools.futuresinstitute.org/UC/unit_cost_db.aspx [cited 2013 Oct 19].
  • 84.Binagwaho A, Pegurri E, Muita J, Bertozzi S. Male circumcision at different ages in Rwanda: a cost-effectiveness study. PLoS Med. 2010;7:e1000211 10.1371/journal.pmed.1000211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Martin G, Bollinger L, Pandit-Rajani T, Tshehlo R, Stover J. Costing male circumcision in Lesotho and implications for the cost-effectiveness of circumcision as an HIV intervention. Washington (DC): United States Agency for International Development; 2007. Available from: http://www.aidstar-one.com/sites/default/files/410_1_Lesotho_MC_Costing_FINAL_10_11_07.pdf [cited 2013 Oct 19].
  • 86.Bollinger L, Stover, J. The potential cost and impact of expanding male circumcision in South Africa. Washington (DC): United States Agency for International Development; 2010. Available from: http://www.malecircumcision.org/programs/documents/South_Africa11209.pdf [cited 2013 Oct 19].
  • 87.Assessing potential impact and costs of scaling-up medical male circumcision services in Uganda. Washington (DC): United States Agency for International Development; 2010. [Google Scholar]
  • 88.Costing male circumcision in Zimbabwe and impacts of scaling up the circumcision program. Washington (DC): United States Agency for International Development; 2010. [Google Scholar]
  • 89.Orlando S, Marazzi MC, Mancinelli S, Liotta G, Ceffa S, Giglio P,et al. Cost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-Project Malawi. J Acquir Immune Defic Syndr. 2010;55:631-4 10.1097/QAI.0b013e3181f9f9f5 [DOI] [PubMed] [Google Scholar]
  • 90.Desmond C, Franklin L, Steinberg M. The prevention of mother-to-child HIV transmission: costing the service in four sites in South Africa. Durban: Health Systems Trust; 2004. Available from: http://www.hst.org.za/sites/default/files/PMTCT_Costing.pdf [cited 2013 Oct 19].
  • 91.Dandona L, Kumar SG, Ramesh YK, Rao MC, Marseille E, Kahn JG,et al. Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India. BMC Health Serv Res. 2008;8:26 10.1186/1472-6963-8-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Bautista-Arredondo S, Dmytraczenko T, Kombe G, Bertozzi SM. Costing of scaling up HIV/AIDS treatment in Mexico. Salud Publica Mex. 2008;50Suppl 4;S437-44 10.1590/S0036-36342008001000004 [DOI] [PubMed] [Google Scholar]
  • 93.Menzies NA, Berruti AA, Blandford JM. The determinants of HIV treatment costs in resource limited settings. PLoS One. 2012;7:e48726 10.1371/journal.pone.0048726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.McMennamin T, Alexander F, Fritsche G. Rwanda HIV/PBF Project: cost and revenue analysis in six Rwandan health centers: 2005 costs and revenues. Washington: United States Agency for International Development ; 2007. Available from: http://www.umuganga.com/docs/statiscs1.pdf [cited 2013 Oct 19].
  • 95.Minh HV, Bach TX, Mai NY, Wright P. The cost of providing HIV/AIDS counseling and testing services in Vietnam. Value in Health Regional Issues. 2012;1:36-40 10.1016/j.vhri.2012.03.012 [DOI] [PubMed] [Google Scholar]
  • 96.Marseille E, Dandona L, Marshall N, Gaist P, Bautista-Arredondo S, Rollins B,et al. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res. 2007;7:108 10.1186/1472-6963-7-108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Wilkinson D, Floyd K, Gilks CF. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS. 1998;12:1675-82 10.1097/00002030-199813000-00016 [DOI] [PubMed] [Google Scholar]
  • 98.Robberstad B, Evjen-Olsen B. Preventing mother to child transmission of HIV with highly active antiretroviral treatment in Tanzania – a prospective cost-effectiveness study. J Acquir Immune Defic Syndr. 2010;55:397-403 10.1097/QAI.0b013e3181eef4d3 [DOI] [PubMed] [Google Scholar]
  • 99.Stringer EM, Sinkala M, Stringer JS, Mzyece E, Makuka I, Goldenberg RL,et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS. 2003;17:1377-82 10.1097/00002030-200306130-00012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Nakakeeto ON, Umaranayake L. The global strategy to eliminate HIV infection in infants and young children: a seven-country assessment of costs and feasibility. AIDS. 2009;23:987-95 10.1097/QAD.0b013e32832a17e9 [DOI] [PubMed] [Google Scholar]
  • 101.Task shifting: rational redistribution of tasks among health workforce teams: global recommendations and guidelines. Geneva: World Health Organization; 2008. [Google Scholar]
  • 102.Zachariah R, Ford N, Philips M, Lynch S, Massaquoi M, Janssens V,et al. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2009;103:549-58 10.1016/j.trstmh.2008.09.019 [DOI] [PubMed] [Google Scholar]
  • 103.Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D,et al. ; ART-LINC, IeDEA. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-67 10.2471/BLT.07.044248 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES